nctId,briefTitle,conditions,specialty,clean_text
NCT04095650,A New Model to Reach Vulnerable Older Adults With Pain Self-management Support,Chronic Pain,Other,"Inclusion: * English-proficient * Age >= 60 years * Ambulatory with or without assistive device * Community-living * Have a cell or landline phone * Have Internet access (home or elsewhere) * Self-reported chronic musculoskeletal pain (pain in muscles or joints for > 3 months); >4 (0-10 scale) average pain level over last week; >1 day/previous 30 when pain made it difficult to do usual activities * Ability to attend a one-time study orientation session Exclusion: * Serious acute illness or hospitalization in last month * Planned surgery in next three months * Significant cognitive impairment as indicated by affirmative response to question: ""Do you have significant difficulties with your memory that get in the way of your usual daily activities?"" * Other severe physical or psychiatric disorder judged by study team to pose significant barrier to deriving program benefit."
NCT03007459,The Health of Competitive Fitness Athletes,"Resting Metabolic Rate; Bone Mineral Density, Low, Susceptibility to; Body Image; Perfectionism; Depression; Eating Disorder; Exercise-Related Amenorrhea; Exercise Addiction; Binge Eating; Dietary Amenorrhea; Dietary Deficiency",Other,"Inclusion: * Fitness athletes: planning to compete in fitness sport during spring or fall 2017 * Controls: being regular physically active (exercise >2 times/week during last year) with a BMI between 17,5-30 Exclusion: * Controls: having competed in fitness sports previously or planning to do in the future, or working as a personal trainer. * Not able to meet at the Norwegian School of Sport Sciences for baseline and follow up screenings. * Being pregnant or nursing * Metabolic related diseases"
NCT03364218,Nebulized N-Acetyl Cysteine for Bronchiolitis in Inpatient Hospital Use,Bronchiolitis Acute,Other,"Inclusion: * Full term new born neonates up to patients < 2yrs * Respiratory score ≥2 * Otherwise healthy with new respiratory illness Exclusion: * Prematurity <34 weeks for patients <6 months age. * h/o congenital heart disease requiring baseline medication * Patient received diagnosis of Asthma or reactive airway disease in past. * Anatomic airway defect. * Immunodeficiency * Chronic lung disease * Patients who have had previous bronchiolitis < 4 weeks ago * Patients intubated for acute bronchiolitis during the current admission. * h/o Larynogomlacia, bronchomalacia or tracheomalacia."
NCT04484142,Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05),Non-small Cell Lung Cancer,Oncology,"Inclusion: Participants eligible for inclusion in the study must meet all inclusion criteria for this study. * Sign and date the inform consent form (ICF) prior to the start of any study- specific qualification procedures. * Adults ≥18 years (if the legal age of consent is >18 years old, then follow local regulatory requirements) * Has pathologically documented NSCLC that: 1. Has stage IIIB, IIIC, or stage IV NSCLC disease at the time of enrollment (based on the American Joint Committee on Cancer, Eighth Edition). 2. Has one or more of the following documented activating genomic alterations: EGFR, ALK, ROS1, NTRK, BRAF, MET exon 14 skipping, or RET. KRAS mutations in the absence of any of the genomic alterations specified above will be excluded. Overexpression of EGFR, in the absence of activating mutations, is NOT sufficient for enrollment. Participants who have not received osimertinib should be evaluated for the presence of EGFR T790M mutation after relapse/progression on/after the most recent EGFR tyrosine kinase inhibitor (TKI), unless the participant is already known to be positive with document results for this mutation or unless osimertinib is not locally approved. * Has documentation of radiographic disease progression while on or after receiving the most recent treatment regimen for advanced or metastatic NSCLC. * Participant must meet the following for advanced or metastatic NSCLC: 1. Has been treated with at least one but no more than two cytotoxic agent-containing therapy in the metastatic setting: * One platinum-containing regimen (either as monotherapy or combination therapy). * May have received up to one additional line of cytotoxic agent-containing therapy. * Those who received a platinum-containing regimen as adjuvant therapy for early stage disease must have relapsed or progressed while on the treatment or within 6 months of the last dose OR received at least one additional course of platinum-containing therapy (which may or may not be same as in the adjuvant setting) for relapsed/progressive disease. 2. May have received up to one checkpoint inhibitor (CPI)-containing regimen (may be in combination with a cytotoxic agent as part of a regimen described above or as an additional CPI regimen without a cytotoxic agent). 3. Has been treated with 1 or more lines of non-CPI targeted therapy that is locally approved for the participant's applicable genomic alteration at the time of screening: * Those who received a targeted agent for the applicable genomic alterations in the study as adjuvant therapy for early stage disease must have relapsed or progressed while on the treatment or within 6 months of the last dose OR received at least one additional course of targeted therapy for the same genomic alterations (which may or may not be same agent used in the adjuvant setting) for relapsed/progressive disease. * Participants who have been treated with a prior TKI must receive additional targeted therapy, if clinically appropriate, for the genomic alterations that are considered amenable or the participant will not be allowed in the study. * Must undergo a mandatory pre-treatment tumor biopsy procedure or if available, a tumor biopsy that was recently collected (within 3 months of screening) after completion of the most recent anticancer treatment regimen and that has a minimum of 10 × 4 micron sections or a tissue block equivalent of 10 × 4 micron sections may be substituted for the mandatory biopsy collected during screening. * Measurable disease based on local imaging assessment using RECIST v1.1. * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 - 1 at screening. Exclusion: Participants meeting any exclusion criteria for this study will be excluded from this study. * Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Participants with clinically inactive brain metastases may be included in the study. * Has leptomeningeal carcinomatosis. * Has prior treatment with: 1. Any chemotherapeutic agent targeting topoisomerase I, including antibody drug conjugate (ADC) containing such agent. 2. TROP2-targeted therapy. * Uncontrolled or significant cardiovascular disease: 1. History of myocardial infarction within 6 months prior to Cycle 1 Day 1. 2. History of uncontrolled angina pectoris within 6 months prior to Cycle 1 Day 1. 3. Symptomatic congestive heart failure (CHF) (New York Heart Association Class II to IV) at screening. Participants with a history of Class II to IV CHF prior to screening must have returned to Class I CHF and have LVEF ≥50% (by either an ECHO or MUGA scan within 28 days of Cycle 1 Day 1) in order to be eligible. 4. History of serious cardiac arrhythmia requiring treatment. 5. LVEF 180 mmHg or diastolic blood pressure >110 mmHg). * Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. * Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses * Clinically significant corneal disease. * Has other primary malignancies, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other solid tumors curatively treated, with no evidence of disease for ≥3 years."
NCT06882850,Immunomodulation During Pregnancy,Aspirin; Pregnancy Complications; Immunology,Other,"Inclusion: - Singleton pregnancy * Patients attending prenatal consultations at the Obstetrics Service A of CHUC, with the first consultation occurring before 14 weeks of gestation * Gestational age determined by first-trimester ultrasound * Study group: Women classified as high risk for PE according to clinical/historical criteria and the Fetal Medicine Foundation algorithm. LDA-naïve. Exclusion: Multiple pregnancy * Autoimmune diseases * Prior use of LDA or other immunomodulatory medication before potential recruitment * History of spontaneous miscarriages and/or medical termination of pregnancy * Fetal malformation"
NCT01060189,Hemostatic Effects of Ulinastatin and Tranexamic Acid in Cardiac Surgery,Hemostasis,Other,Inclusion: * Atrial or ventricular septum defect patients requiring cardiac surgery with CPB * Rheumatic or recessive valvular patients requiring valvular repair or replacement with CPB * Coronary artery disease patients requiring coronary revascularization surgery with CPB Exclusion: * Non-primary cardiac surgery * Definite liver or renal dysfunction * Disorder in coagulation function * Allergy * Pregnancy or lactation * Disabled in spirit or law * Fatal conditions such as tumour
NCT05523635,Post Market Clinical Evaluation of Gamma 4,Femoral Fracture,Other,"Inclusion: * Subject is a male or non-pregnant female age 18 years or older at the time of surgery; * Subject is willing and able to give written informed consent and comply with the requirements of this Clinical Investigation Plan; and * Subject has or is intended to be treated with the Gamma 4 System in accordance with its legally approved Indication for Use (IFU). Indication For Use in the United States and Canada: The Gamma4 System is indicated for the treatment of stable and unstable fractures as well as for stabilization of bones and correction of bone deformities in the intracapsular, trochanteric, subtrochanteric and shaft regions of the femur (including osteoporotic and osteopenic bone). Exclusion: * Subject is currently enrolled in or plans to enroll in any concurrent drug and/or device clinical investigation that, in the opinion of the Investigator, may confound results * Subject with exclusion criteria required by local law * Subject who is, or will be, inaccessible for follow-up * Per the Investigator, the subject is in poor general health or undergoing any concurrent disease that would place the subject in excessive risk to surgery (i.e., significant circulatory problems, cardiac disease). * Any active or suspected latent infection or marked local inflammation in or about the affected area * Compromised vascularity that would inhibit adequate blood supply to the fracture or the operative site * Bone stock compromised by disease, infection or prior implantation that cannot provide adequate support and/or fixation of the devices * Material sensitivity, documented or suspected * Patients having inadequate tissue coverage over the operative site * Implant utilization that would interfere with anatomical structures or physiological performance * Any mental or neuromuscular disorder which would create an unacceptable risk of fixation failure or complications in postoperative care * Other medical or surgical conditions which would preclude the potential benefit of surgery."
NCT05599191,A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough,Cough; Refractory Chronic Cough,Other,"Inclusion: * Capable of giving signed informed consent * Refractory chronic cough (including unexplained chronic cough) for at least one year * Women of child-bearing potential must use a highly effective contraception method during the study and for at least 14 days after the last dose Exclusion: * Current smoker/vaper (all forms of smoking and inhaled substances, including, cannabis/tobacco smoke and nicotine vapors) or individuals who have given up smoking within the past 6 months, or those with >20 pack-year smoking history * Diagnosis of chronic obstructive pulmonary disease, bronchiectasis, chronic bronchitis, cystic fibrosis, pulmonary sarcoidosis, idiopathic pulmonary fibrosis, uncontrolled asthma, or other significant or progressive airway/respiratory disorder that might affect cough based on clinician assessment * Respiratory tract infection within 4 weeks before screening * Laboratory confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection at screening * History of malignancy in the last 5 years * History of alcohol or drug abuse within the last 3 years * Has a positive serologic test for human immunodeficiency virus (HIV), hepatitis B virus surface antigen, or hepatitis C virus. * Previous participation in a BLU-5937 trial"
NCT02734888,Arterial Inflammation and E-Cigarettes,Arterial Inflammation,Other,Inclusion: Healthy * Nonsmokers OR * Daily e-cigarette user OR * Daily tobacco cigarette smoker Exclusion: * Cardiac disease * Respiratory Disease * Diabetes mellitus
NCT00708513,Intraoperative Cell Saver Autotransfusion Use for Major Surgical Oncology Operations.,Pancreaticoduodenectomy; Pancreatectomy; Esophagectomy; Gastrectomy; Hepatectomy,Other,"Inclusion: 1. Subject is undergoing a major surgical oncology procedure and has potential for extensive blood loss. 2. Subject is ≥ 18 years of age. 3. Subject or Subject's Legally Authorized Representative (LAR) has signed an IRB-approved informed consent form. Exclusion: 1. Subject has medical, social, or psychological factors that, in the opinion of the Investigator, could impact safety or compliance with study procedures. 2. Subject is < 18 years of age. 3. Subject or Subject's LAR did not sign IRB-approved informed consent form."
NCT03876561,"""Impact of Pelvic Floor Prehabilitation Using Biofeedback on the Severity of the Low Anterior Resection Syndrome in Patients Undergoing a Total Mesorectal Excision for Rectal Cancer""",Rectal Cancer,Oncology,Inclusion: * Age between 18 and 80 years old * Total mesorectal excision with colorectal or coloanal anastomosis protected by an ileostomy or a colostomy for rectal cancer * Absence of anastomotic leakage or stenosis * Informed consent to participate in the study * Social security insurance affiliation Exclusion: * History of anal incontinence and/or fecal urgency and/or chronic diarrhea requiring a specific treatment before rectal cancer management * Absence of ileostomy or colostomy * Anastomotic leakage * Sensorial or cognitive disorders impeding pelvic floor rehabilitation exercise * Pregnant women * Minors * Adults under guardianship
NCT06798259,Autonomic Dysfunction in Patients With Migraine: Cardiovascular and Neurophysiology Assessment,Migraine Headache,Other,"Inclusion: * 1.fulfilling ICHD-3 criteria for migraine 2. migraine for at least 3 months. Exclusion: brain imaging showing structural brain lesions. .medications that could impact autonomic function such as tricyclic antidepressants, anticholinergics, or opioids. * Patients with concomitant medical illness causing autonomic dysfunction such as: diabetes, cardiovascular, demyelinating or degenerative neurological disorders. * Contraindications for performing the tilt test * Pregnant patients."
NCT04592068,AI Classifies Multi-Retinal Diseases,Deep Learning; Retinal Diseases,Other,Inclusion: * fundus photography around 45° field which covers optic disc and macula * complete patient identification information; Exclusion: * incomplete patient identification information
NCT05331235,Blood Transfusions in Preterm Infants,Red Blood Cells; Preterm,Other,"Inclusion: * Grower preterm infants Exclusion: * Severe illness, Hypovolemic shock, Hypoxia, Oxygen therapy, Surgical intervention"
NCT04456868,Neurophysiological Markers in the Depressive Episode Characterized by Anhedonic Drug Resistance: Evaluation of Motor Skills and P300 Wave,Bipolar Anhedonic Depression,Other,"Inclusion: * Healthy volunteers: * Person who is ≥ 18 years old and ≤ 70 years old * Subject without neurological history * Subject without psychiatric history in the semi-structured interview Mini International Neuropsychiatric Interview (MINI). * Subject having read and understood the newsletter and signed the consent form * Subject affiliated to a social security scheme. * Subject capable of understanding spoken and written French. * Woman of reproductive age with effective contraception as defined by the WHO, for at least three months or postmenopausal. Patients with drug-resistant bipolar anhedonic depression: * Patient whose age is ≥ 18 years and ≤ 70 years. * Patient with depression meeting DSM-5 criteria (Appendix 4) evolving in the context of bipolar disorder. * Patient with a resistance level greater than or equal to 1 according to the Pacchiarotti classification. * Patient with an SHAPS anhedonia score greater than 5/14. * Patient with no other psychiatric pathology in the semi-structured interview Mini International Neuropsychiatric Interview (MINI). * Stable lithium treatment in the 7 days preceding the inclusion visit. * Patient who has not received treatment with electroconvulsive therapy in the 2 months preceding the inclusion visit. * Patient having a normal neurological examination. * Patient who has read and understood the information letter and signed the consent form. * Patient affiliated to a social security scheme. * Patient able to understand spoken and written French. * Woman of reproductive age with effective contraception as defined by the WHO, for at least three months or postmenopausal.Patient dont l'âge est ≥ 18 ans et ≤ 70 ans. Patients with drug-resistant bipolar depression of the non-anhedonic type: * Patient whose age is ≥ 18 years and ≤ 70 years. * Presence of a depression meeting the criteria of DSM-5 (Annex 4) evolving in the context of bipolar disorder. * Patient with a resistance level greater than or equal to 1 according to the Pacchiarotti classification. * Patient with SHAPS anhedonia score less than or equal to 3/14. * Absence of another psychiatric pathology in the semi-structured interview Mini International Neuropsychiatric Interview (MINI). * Stable lithium treatment in the 7 days preceding the inclusion visit. * Patient who has not received treatment with electroconvulsive therapy in the 2 months preceding the inclusion visit. * Patient having a normal neurological examination. * Patient who has read and understood the information letter and signed the consent form. * Patient affiliated to a social security scheme. * Patient able to understand spoken and written French. * Woman of reproductive age with effective contraception as defined by the WHO, for at least three months. Patients with Parkinson's disease : * Patient whose age is ≥ 18 years and ≤ 70 years. * Patient with idiopathic Parkinson's disease as defined by the diagnostic criteria of the United Kingdom Parkinson's Disease Society Brain Bank (UKPDSBB) (Annex 8). * Patient with Parkinson's disease stage less than 3 (mild or moderate severity) according to the classification of Hoehn & Yahr (Annex 7). * Patient treated with L-DOPA associated with a dopa-decarboxylase inhibitor (DDC) and who has not changed antiparkinsonian treatment for at least 1 month before the inclusion visit. * Patient with no neurological disorders other than those induced by Parkinson's disease. * Patient without depression defined by a score less than or equal to 8 on the Montgomery-Åsberg Depression Rating Scale (MADRS) (Annex 10). * Patient with no psychiatric pathology at the semi-structured interview Mini International Neuropsychiatric Interview (MINI) (Annex 9). * Patient who has read and understood the information letter and signed the consent form. * Patient affiliated to a social security scheme. * Patient able to understand spoken and written French. * Woman of childbearing age with effective contraception as defined by the WHO, for at least three months. Exclusion: * Healthy volunteers: * Person with a psychiatric disorder in the semi-structured interview Mini International Neuropsychiatric Interview (MINI) (Annex 9). * Person deprived of their liberty by an administrative or judicial decision or person placed under the protection of justice / sub-tutorship or curatorship. * Subjects with poor understanding of spoken or written French * Existence of a neurological, rheumatological, orthopedic or psychiatric history, presence of a severe progressive pathology which can modify brain activity or gait parameters. * Woman of childbearing age not taking effective contraception according to the WHO definition (estrogen-progestogens or intrauterine device or tubal ligation), pregnant (positive urine pregnancy test) or breastfeeding. * Taking unauthorized treatment during the study and: * In the 7 days preceding inclusion for dopamine agonists, MAOIs, antiepileptics, antidepressants, benzodiazepines and L-DOPA combined with a dopa decarboxylase (DDC) or catechol-O-methyl transferase inhibitor (COMT). * In the 28 days preceding inclusion for amphetamines, antivirals, antiemetics. * In the 2 months preceding inclusion for electroconvulsive therapy * In the 6 months prior to inclusion for antipsychotics. * Dependence on a substance other than nicotine. Patients with drug-resistant bipolar anhedonic depression: * Patient with depression with psychotic characteristics. * Patient deprived of liberty by an administrative or judicial decision or person placed under the protection of justice / sub-tutorship or curatorship. * Subjects with poor understanding of spoken or written French * Patient with SHAPS anhedonia score less than or equal to 5/14 (Annex 2). * Patient with a neurological, rheumatological, orthopedic or psychiatric history, presence of a severe progressive pathology which can modify brain activity or gait parameters. * Woman of childbearing age not taking effective contraception according to the WHO definition (estrogen-progestogens or intrauterine device or tubal ligation), pregnant (positive urine pregnancy test) or breastfeeding. * Subject with a history of allergy or hypersensitivity to the active substance in DOPACIS (18Fluorodopa) or to any of its excipients. * Taking unauthorized treatment during the study and: * In the 7 days preceding inclusion for dopamine agonists, MAOIs, antiepileptics, antidepressants, benzodiazepines and L-DOPA combined with a dopa decarboxylase (DDC) or catechol-O-methyl transferase inhibitor (COMT). * In the 28 days preceding inclusion for amphetamines, antivirals, antiemetics. * In the 2 months preceding inclusion for electroconvulsive therapy * In the 6 months prior to inclusion for antipsychotics. * Dependence on a substance other than nicotine. Patients with drug-resistant bipolar depression of the non-anhedonic type: * Pa Patient with depression with psychotic characteristics. * Patient deprived of liberty by an administrative or judicial decision or person placed under the protection of justice / sub-tutorship or curatorship. * Subjects with poor understanding of spoken or written French * Patient with SHAPS anhedonia score less than or equal to 5/14 (Annex 2). * Patient with a neurological, rheumatological, orthopedic or psychiatric history, presence of a severe progressive pathology which can modify brain activity or gait parameters. * Woman of childbearing age not taking effective contraception according to the WHO definition (estrogen-progestogens or intrauterine device or tubal ligation), pregnant (positive urine pregnancy test) or breastfeeding. * Subject with a history of allergy or hypersensitivity to the active substance in DOPACIS (18Fluorodopa) or to any of its excipients. * Taking unauthorized treatment during the study and: * In the 7 days preceding inclusion for dopamine agonists, MAOIs, antiepileptics, antidepressants, benzodiazepines and L-DOPA combined with a dopa decarboxylase (DDC) or catechol-O-methyl transferase inhibitor (COMT). * In the 28 days preceding inclusion for amphetamines, antivirals, antiemetics. * In the 2 months preceding inclusion for electroconvulsive therapy * In the 6 months prior to inclusion for antipsychotics. * Dependence on a substance other than nicotine. Patients with Parkinson's disease: * Patient with depression. * Patient deprived of liberty by an administrative or judicial decision or person placed under the protection of justice / sub-tutorship or curatorship. * Subjects with poor understanding of spoken or written French * Severe form of Parkinson's disease with a Hoehn and Yhar upper or equal 4 (Annex 7). * Patient with other neurological, rheumatological, orthopedic or psychiatric history, presence of a severe progressive pathology which can modify brain activity or gait parameters. * Woman of childbearing age not taking effective contraception according to the WHO definition (estrogen-progestogens or intrauterine device or tubal ligation), pregnant (positive urine pregnancy test) or breastfeeding. * Subject with a history of allergy or hypersensitivity to the active substance in DOPACIS (18Fluorodopa) or to any of its excipients. * Taking unauthorized treatment during the study and: * In the 7 days preceding inclusion for dopamine agonists, MAOIs, antiepileptics, antidepressants, benzodiazepines and L-DOPA combined with a dopa decarboxylase (DDC) or catechol-O-methyl transferase inhibitor (COMT). * In the 28 days preceding inclusion for amphetamines, antivirals, antiemetics. * In the 2 months preceding inclusion for electroconvulsive therapy * In the 6 months prior to inclusion for antipsychotics. * Dependence on a substance other than nicotine."
NCT07353203,Safety and Efficacy of Hip Assist Powered Exoskeleton for Gait Training in Patients With Late Subacute and Chronic Stroke,Chronic Stroke; Subacute Stroke; Exoskeleton,Neurology,"Inclusion: 1. Adults aged 19 to 85 years. 2. Patients with hemiplegia resulting from ischemic or hemorrhagic stroke. 3. Patients in the late subacute or chronic phase, with stroke onset of 3 months or more (in cases of recurrent stroke, based on the most recent event). Functional Ambulation Category (FAC) score of 3 or higher. 4. Patients capable of safely wearing the hip-assist powered exoskeleton and using it with minimal assistance. * Height: 140 cm - 190 cm * Weight: 80 kg or less 5. Patients who were capable of independent walking and had no disability in daily self-care activities prior to stroke onset (based on the last stroke for recurrent patients). (mRS ≤2) 6. Patients who have received approval for study participation from the attending medical staff. Exclusion: 1. Severe cognitive impairment (Mini-Mental State Examination [MMSE] < 10) or severe speech impairment/aphasia. 2. History of major orthopedic surgery, such as hip, knee, or ankle arthroplasty, within the last 3 months. 3. Fractures, open wounds, or unhealed ulcers in the lower extremities. 4. Patients for whom gait training with the powered orthopedic device is difficult due to severe medical conditions, such as cardiovascular or pulmonary diseases. 5. History of osteoporotic fractures. 6. Patients with other neurological diseases affecting gait (e.g., Parkinson's disease, multiple sclerosis, etc.). 7. Any other cases where the investigator deems participation in the study to be inappropriate."
NCT06654908,Insulin Resistance and Resisted Exercise Post Burn,Insulin Resistance,Other,"Inclusion: * Patients ranged from 18-35 years of age. * Patients has waist hip ratio around 0.8 in female and 0.95 in male. * Patient has body mass index (BMI around 25 kg/m2) (J Obes Weight Loss Ther ,2015). * Patients has second degree thermal burn injury (superficial and deep partial thickness). * Patients with around (20% - 40%) of total body surface area (TBSA) burned. * Patients who are able to follow verbal commands. * Patients will have upper limb and trunk burn. * Patients with normal hemoglobin A1C (5.6 %). * Patients should take diet rich protein, omega 3 and should have good sleep. * Patients passed two months post severe burns Exclusion: * - Potential participants were excluded if they reported a leg amputation, anoxic brain injury, psychological disorders, quadriplegia, or severe behavior or cognitive disorders history of heart disease, stroke, diabetes mellitus, or any condition that would prevent them from engaging in an exercise study. * Patients with liver disease, pancreatic disease or any disease affects metabolism. * If they were already engaging in 2 or more planned exercise sessions per week. * Patients with any medication to lower glucose levels. Blood pressure and medications to lower lipid levels"
NCT03895268,Influenza A+B Test Kit Performance Study,Influenza Type A; Influenza Type B,Other,"Inclusion: * Patient is having NPA collected by the hospital as routine testing * Patient or patient's next of kin/guardian is willing and able to give informed consent for participation in the trial. * Patients presented with influenza-like illness, i.e. fever and cough, with onset of illness within 7 days of hospital admission * Male or Female, 18 years of age or above. Exclusion: • Have had influenza-specific treatment."
NCT00958997,Positron Emission Tomography (PET) Imaging of Pancreatic Beta-Cell Mass in Healthy and Type 1 Diabetic Patients,"Diabetes Mellitus, Type 1",Endocrinology,"Inclusion: 1. Patients with Type 1 diabetes may be enrolled if they meet all of the following criteria: * Have a diagnosis of Type 1 diabetes mellitus defined by ADA criteria or judgment of physician; diabetes onset younger than age 18, duration >5 years * Have fasting C-Peptide ≤ 0.1 ng/ml * BMI between 18 and 29 kg/m2 * Able to tolerate PET and MR imaging * No metal implants * No claustrophobia 2. Healthy volunteers may be enrolled if they meeting all of the following criteria: * Have no history of Type 1 diabetes * Fasting blood glucose ≤ 100 mg/dL * Negative islet autoantibody testing * BMI between 18 and 29 kg/m2 * Able to tolerate PET and MR imaging * No history of previous allergic reactions to drugs * No metal implants * No claustrophobia Exclusion: * Clinically significant renal dysfunction; * Clinically significant liver dysfunction as determined by history, physical examination, and standard liver function testing at screening (AST, ALT, Total/Direct Bilirubin, Alkaline Phosphatase); * Coagulopathy; * History of allergic reactions to any drug * Current use of any medications except for insulin for Type 1 diabetes * Clinically significant cardiovascular disease or clinically significant abnormalities on screening ECG (including but not limited to QTc>450 msec); * Clinically significant psychiatric disease; Clinically significant pulmonary, renal or hepatic impairment or cancer, have clinically significant infectious disease, including AIDS or HIV infection, or previous positive test for hepatitis B, hepatitis C, HIV-1, or HIV-2; subjects will be asked about this. No testing will be performed. * Have a history of alcohol or substance abuse or dependence; * Are women of childbearing potential not refraining from sexual activity or not using adequate contraception. Women must not be pregnant (negative serum β-HCG at the time of screen) or lactating at screening, and must agree to take appropriate steps not to become pregnant during the study and for 30 days following the study. * Currently receiving any investigational medications, or have participated in a trial with investigational medications within the last 30 days. * Have received a diagnostic or therapeutic radiopharmaceutical within 7 days prior to participation in this study. * Claustrophobia * Metal implants (pace-maker, artificial joints, non-removable body piercings)"
NCT04138394,VItamin C in Thermal injuRY: The VICToRY Trial,Shock; Thermal Burn,Other,Inclusion: * 18 years of age or older * Deep 2nd and/or 3rd degree burns requiring skin grafting * Minimum burn size of ≥ 20% Total Body Surface Area (TBSA) Exclusion: * >24 hours from admission to participating hospital to consent. * Patients admitted to burn unit >24 from injury or accident. * Patients who are moribund (not expected to survive the next 72 hours). * Pregnancy (pregnancy will be ruled out as part of standard of care) or lactating. * Enrollment in another industry sponsored ICU intervention study. * Receiving high-dose IV vitamin C already (enteral or oral vitamin C is allowed). * Known glucose-6-phosphate dehydrogenase (G6PD) deficiency. * Recent history of kidney stones (within the last year). * Concomitant use of hydroxycobalamin (vitamin B12) for suspected cyanide poisoning.
NCT03687450,Feasibility of a Yoga- and Mindfulness-Based Intervention for Resident Physicians,"Burnout, Professional; Anxiety; Depression; Stress",Other,"Inclusion: * Individuals enrolled in residency programs at Brigham and Women's Hospital, Beth Israel Deaconess, Boston Children's Hospital, or a Harvard Combined Residency Program * Individuals must be willing to not practice mind-body programs other than the intervention during the treatment protocol * Must be proficient in English Exclusion: * Individuals who currently practice yoga, meditation, tai chi, qigong, and other mind-body practices more than 25 hours in the past 6 months"
NCT02415608,Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis,Aggressive Systemic Mastocytosis; Mast Cell Leukemia; Systemic Mastocytosis,Oncology,"Inclusion: * Diagnosis of systemic mastocytosis per 2008 World Health Organization (WHO) criteria. Those with advanced systemic mastocytosis (ASM); mast cell leukemia (MCL); or systemic mastocytosis-associated hematological clonal non-mast cell lineage disease (SM-AHNMD) required to have at least 1 organ damage finding * Serum aspartate transaminase (AST) or alanine transaminase (ALT) ≤ 3.0 x upper limit of normal (ULN); if considered related to ASM/MCL ≤ 5 x ULN * Estimated creatinine clearance ≥ 30 mL/min (Cockcroft-Gault) * Total bilirubin ≤ 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin); if considered related to ASM/MCL ≤ 3 x ULN * Female subjects must be of non-reproductive potential, or if of childbearing potential must have a negative serum pregnancy test upon study entry * Must agree to use highly effective methods of birth control * Written informed consent * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3 * Life expectancy > 12 weeks Exclusion: * Received any investigational agent, chemotherapy, interferon-alpha, or 2-chlorodeoxyadenosine (2-CdA, cladribine) within 30 days prior to day 1; or monoclonal antibody ≤ 6 weeks prior to first administration of study treatment (patients with an AHNMD with progressive leukocytosis who require control of their counts are permitted to receive hydroxyurea) * Diagnosis of AHNMD requiring immediate cytoreductive therapy or targeted drugs (eg, acute myeloid leukemia [AML]) * History of other malignancies, except: * Malignancy treated with curative intent and with no known active disease present for ≥ 3 years before the first dose of study drug, and at low risk for recurrence * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease * Adequately treated carcinoma in situ without evidence of disease * Concurrent systemic immunosuppressant therapy (eg, cyclosporine A, tacrolimus, etc., or chronic administration [> 14 days] of > 10 mg/day of prednisone) within 28 days of the first dose of study drug * Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug * Systemic treatment for infection completed ≤ 14 days before the first dose of study drug * Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4), grade 0 or 1, or to the levels dictated in the inclusion/exclusion criteria with the exception of alopecia * Known bleeding disorders (eg, severe von Willebrand's disease) or severe hemophilia * History of stroke or intracranial hemorrhage within 6 months prior to enrollment * Known history of human immunodeficiency virus (HIV) or * Active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) * Major surgery within 4 weeks of first dose of study drug * Any life-threatening illness, medical condition, or organ system dysfunction that could compromise the subject's safety or put the study outcomes at undue risk * Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to randomization * Unable to swallow capsules or malabsorption syndrome * Disease significantly affecting gastrointestinal function * Resection of the stomach or small bowel * Symptomatic inflammatory bowel disease * Ulcerative colitis * Partial or complete bowel obstruction * Requires treatment with a strong cytochrome P450 (CYP) 3A4/5 inhibitor * Lactating or pregnant * Unwilling or unable to participate in all required study evaluations and procedures * Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local subject privacy regulations) * Known hypersensitivity to any excipient contained in the drug * Received hematopoietic growth factor support within 14 days of day 1 of ibrutinib (Jehovah's witnesses may be given an erythropoiesis-stimulating agent before and during the trial in lieu of red blood cell transfusions but anemia and/or red blood cell (RBC) transfusion dependence cannot be used for response assessment in these patients) * Presence of the factor interacting with poly(A) polymerase alpha (PAPOLA) and cleavage and polyadenylation specific factor 1 (CPSF1) (FIP1L1)-platelet-derived growth factor receptor, alpha polypeptide (PDGFRalpha) fusion even with resistance to imatinib (such patients are no longer defined as systemic mastocytosis by the WHO) * Received any treatment with ibrutinib prior to study entry * The concomitant use of warfarin or other vitamin K antagonists unless felt to be of significant clinical need; low molecular weight heparin or other anticoagulants may be used instead if anticoagulation is required"
NCT02243423,Neonatal Acid-Base Status After C Section With Maternal Tilt vs. Supine,Aortocaval Compression; Fetal Acidosis,Other,"Inclusion: * ASA I and II women aged ≥18 years * Non-laboring * At term (>37 weeks gestation) with singleton pregnancies in cephalic presentation * Scheduled for elective cesarean delivery under spinal anesthesia. * Maternal height will be between 150 - 180 cm and the body mass index (BMI)≤ 40 kg/m2. Exclusion: * Ruptured membranes * Severe polyhydramnios or oligohydramnios * Nonreassuring fetal heart rate * Intrauterine growth restriction * Abnormal lie - e.g. breech, transverse lie * Multiple gestation * Maternal comorbidities: hypertension, preeclampsia, other cardiovascular disease, renal failure, diabetes mellitus> 10 years, severe scoliosis or kyphosis, uterine abnormalities (e.g. large fibroids, bicornuate uterus) * Medications - anti-hypertensive agents * Current smoking or illicit drug use * Failed spinal (sensory level < T6 after 15 minutes), need to convert to general anesthesia before delivery (exclusion from data analysis"
NCT03754010,Does Hyaluronic Acid Affect Periodontal Treatment?,Periodontitis,Other,"Inclusion: * Systemically healthy * moderate-to-severe periodontitis * at least five sites with ≥5mm probing depth (PD) * at least ≥20 teeth * Stage II-III periodontitis according to the 2017 World Workshop * Age between18-55 Exclusion: * receiving systemic or local antibiotics within the past six months * prior surgical or non-surgical periodontal treatment within the past six months * smoking * pregnancy * lactation * age ≤18 years or ≥55 years * hypertension * known chronic systemic diseases (i.e., diabetes mellitus, rheumatoid arthritis), - - known hypersensitivity to one of the ingredients of the HA preparation."
NCT06927440,National Multicenter Registry for Pediatric End-Stage Heart Failure in China,Heart Failure; Children,Cardiology,"Inclusion: Patients who meet any of the following criteria despite receiving optimal guideline-directed medical therapy (GDMT): Severe and persistent heart failure symptoms [New York Heart Association (NYHA) Class III (advanced) or IV]; Significant cardiac dysfunction, defined as: Left ventricular ejection fraction ≤30% Isolated right ventricular failure Non-operable severe valvular or congenital abnormalities Persistently elevated B-type natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP) levels Severe diastolic dysfunction or left ventricular structural abnormalities (based on ESC definitions for heart failure with preserved ejection fraction [HFpEF] and heart failure with mildly reduced ejection fraction [HFmrEF]); Requirement of: High-dose intravenous diuretics (or combination diuretic therapy) for pulmonary/systemic congestion, OR Inotropic/vasoactive agents for low cardiac output, OR Management of malignant arrhythmias Resulting in >1 unplanned hospital visits or admissions within the past 12 months; Severely impaired mobility due to cardiac causes with either: Inability to ambulate, OR 6-minute walk distance <300 m, OR Peak oxygen consumption (PvO₂) <12-14 mL/kg/min. - Exclusion: Concurrent life-limiting systemic disorders Structural cardiac lesions with indication for surgical/interventional correction"
NCT04988425,TNFα Monoclonal Antibody for Acute Spinal Cord Injury,Spinal Cord Injuries,Other,"Inclusion: * Patients aged between 18 and 60 years * Traumatic spinal cord injury * ASIA Impairment Scale A-D * The injury must be within two weeks * Patients submitted written informed consent Exclusion: * Traumatic spinal cord injury with brain injury or peripheral nerve injury * Patients with severe multiple injuries and unstable vital signs * Non-traumatic spinal cord injury caused by spinal tumors, hematoma, myelitis, etc. * Patients with central spinal cord injury * Patients with a completely transected spinal cord * Patients with fever or acute infection * Ongoing infectious disease, such as tuberculosis, HIV, hepatitis, syphilis, etc. * Patients with malignant tumour * Patients with neurodegenerative diseases, or any neuropathies * Patients with ankylosing spondylitis * Patients with a previous history of spinal surgery"
NCT03050866,Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs),Circulating Tumor Cell; Metastatic Prostate Cancer,Oncology,"Inclusion: * Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features. * Continued androgen deprivation therapy either by luteinizing hormone-releasing hormone (LHRH) agonists/antagonists or orchiectomy. * Serum testosterone <50 ng/mL (1.7 nmol/L) within 21 days before prescreening. * Age ≥18 years * Received prior docetaxel, and experienced disease progression during or after treatment with docetaxel. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (appendix A) * Written informed consent according to ICH-GCP (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice) before study treatment and any study specific procedures Exclusion: * Geographical, psychological or other non-medical conditions interfering with follow-up * Uncontrolled severe illness or medical condition (including uncontrolled diabetes mellitus or active systemic or local bacterial, viral, fungal - or yeast infection) * Symptomatic central nervous system (CNS) metastases or history of psychiatric disorder that would prohibit the understanding and giving of informed consent. * Chemotherapy or immunotherapy (other than LHRH analogues) within the last 4 weeks before study inclusion. * Prior treatment with cabazitaxel * Treatment with both abiraterone and enzalutamide in the post-docetaxel setting * Radiotherapy to 40% or more of the bone marrow * Known hypersensitivity to corticosteroids * History of severe hypersensitivity reaction (≥grade 3) to docetaxel * History of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing drugs * Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5 (a one week wash-out period is necessary for patients who are already on these treatments) * Concomitant vaccination with yellow fever vaccine * Abnormal liver functions * Abnormal hematological blood counts"
NCT06385535,Clinical Characteristics and Temporal Properties of Individual Tics in Persistent Tic Disorder,Tics; Tic Disorders; Vocal Tic; Motor Tic; Tourette Syndrome; Tourette Syndrome in Children; Tourette Syndrome in Adolescence; Tics/Tremor,Other,"Inclusion: * 8 to 12 years old child who meets the criteria for diagnosis of a persistent tic disorder (e.g., persistent motor/vocal tic disorder or Tourette's disorder; i.e., engages in motor and or vocal tics that have been present for at least one year) * The child's tics initially onset before age 10. * The child currently engages in at least four different motor and/or vocal tics per minute, on average, during a 10-minute observation period. * The child has a minimum Total Tic Severity Score of 20 on the Yale Global Tic Severity Scale (10 for motor or vocal tics only) * If the child is on tic-suppressing or psychotropic medication, the dose has been stable for at least 6 weeks with no changes or planned changes in medication status during the study period. * Parent and child read and speak fluent English. * The parent is 18+ years of age. * Access to a private computer with high-speed internet access and private setting. Exclusion: * If, based on the assessment of the study investigators, the child has any serious psychiatric or neurological condition that would interfere with study participation (e.g., unmanaged attention-deficit hyperactivity disorder) * The child has a self- or parent-reported history of, or is reasonably suspected to have or meet criteria for, functional neurological symptom disorder. * The child has received more than two sessions of behavioral treatment for tics for which tic suppression was a primary component. * The child has a Total Tic Severity Score of 40+ on the Yale Global Tic Severity Scale (20+ for motor/vocal tics only)."
NCT07296224,Scannographic Predictive Factors of Change of Strategy During Metabolic Bariatric Surgery,Obesity & Overweight,Other,Inclusion: * All adult patients scheduled for LRYGB surgery at the Nancy University Hospital between 1st October 2012 and 31st December 2022 who underwent a change in intraoperative surgical strategy * patient who did not object to the collection of their data. * patients over the age of 18 Exclusion: * Patients who did not have a preoperative scan * patients who were lost to follow-up within 6 months of surgery
NCT01133769,Operative Versus Non-Operative Treatment of Clavicle Fracture in PolyTrauma,Clavicle Fracture; Chest Injury,Other,"Inclusion: 1. Patients males and females of any race. 2. Patients between ages 18 and 80 3. Patients who present with a unilateral clavicle fractures which are >2cm displaced, >2cm shortened, significantly comminuted, or are tenting the skin or which are bilateral and with associated chest injury and with or without additional injuries to the abdomen, pelvis or extremities will be approached for the study. Exclusion: 1. Severe brain injury (GCS less than or equal to 13) 2. Intubated patients 3. Injury precluding operative fixation within 7 days of admission 4. Open clavicle fracture 5. Spinal cord injuries 6. Age <18 or greater than or equal to 80"
NCT06502483,PRISM for Depression and Anxiety in Young Adults With Cancer,"Cancer Diagnosis; Non-Metastatic Neoplasm; Anxiety; Anxiety Disorders; Depression; Depressive Disorder; Depression, Anxiety; Desmoid",Oncology,"Inclusion: for Participants: 1. 18-39 years of age 2. Speak and comprehend English sufficiently to be able to complete study procedures and participate in the program in English* 3. Have been diagnosed with cancer or desmoid tumor at least 6 or more weeks ago 4. Currently receiving treatment or has completed treatment for cancer or desmoid tumor no more than 6 months ago 5. Score 10-24 (with question #9 not endorsed, or 0) on the PHQ-9 (Kroenke et al., 1999) or/and score 10-21 on the GAD-7 (Spitzer et al., 2006) during the initial screening assessment. Participant Exclusion: 1. Adults unable to consent, individuals who are not yet adults (age <18), pregnant women, and prisoners. 2. Individuals who score less than 10 on both PHQ-9 and GAD-7. 3. Individuals who are diagnosed with cancer less than 6 weeks at the time of screening (we will be able to approach them again after 6 weeks since diagnosis has passed), or those who completed treatment more than 6 months ago will also be ineligible for this study; they will be offered resources for support, if desired. 5) Individuals who report any suicidality (ideation, plan, and/or intent) on PHQ-9 screen (i.e., endorse anything more than 0 for question #9) at the time of the eligibility screening will also be excluded from the current study, and the appropriate safety measures and/or referral to a mental health provider will be made (see section 14.1 for more details on the procedure). Inclusion Criteria for Support Person: -≥ 18 years of age -A friend or family member invited by the study participant to join the 6th PRISM session"
NCT06207669,Music Therapy for Individuals Receiving Hemodialysis Treatment,Hemodialysis Complication,Other,"Inclusion: * Being 18 years or older, * Having been receiving hemodialysis treatment for at least 6 months, * Being literate, * Being open to collaboration, Exclusion: * Having sensory loss related to vision, hearing and communication, * Having a psychiatric illness."
NCT00307970,Impact of Anti-static Chamber/Mask,Asthma,Pulmonology,"Inclusion: * children 1-6 years old; adequately controlled persistent asthma; currently receiving FP delivered by CFC MDI attached to valved-holding chamber/mask; ability to use chamber with mask effectively Exclusion: * inadequately controlled asthma: nocturnal awakening > 2 nights/month, prn albuterol use > 2x/week, more than 2 short courses of oral corticosteroids in previous 3 months, missing a dose on more than one occasion, increase in asthma symptoms during study, inability to discontinue intranasal or dermal fluticasone for 3 days"
NCT05139680,A Study to Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis,"Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype",Other,"Inclusion: * Age ≥18 years at diagnosis * Diagnosed with ATTRv-CM, mixed phenotype * Treated with tafamidis (VYNDAQEL 80 mg [four 20-mg tafamidis meglumine capsules] orally once daily or VYNDAMAX 61 mg [one 61-mg tafamidis capsule] orally once daily) for ≥6 months * Have had ≥1 pre- and ≥2 post-treatment neurologic assessments Exclusion: * History of organ transplant * Wild-type TTR genotype * Individuals who are non-ambulatory * Prior treatment with any disease-modifying therapy (investigational or approved) alone or in combination, except tafamidis, as either VYNDAQEL 80 mg (four 20-mg tafamidis meglumine capsules) orally once daily or VYNDAMAX 61 mg (one 61-mg tafamidis capsule) orally once daily * Peripheral neuropathy attributed to causes other than ATTR amyloidosis (e.g., diabetes mellitus, B12 deficiency, HIV infection)"
NCT05225597,The Effect of Intracameral Carbachol and Epinephrine on Choroidal Thickness,Epinephrine Toxicity; Cataract; Carbachol Adverse Reaction; Choroid Disease,Other,"Inclusion: * over 18 years old * patients with cataracts Exclusion: * hypertension and diabetes * ocular problems such as uveitis, glaucoma, amblyopia * maculopathy, retinal dystrophy * any previous ocular surgery * eye trauma * congenital cataracts"
NCT02140580,OPTIMIST-A Trial: Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on CPAP,Bronchopulmonary Dysplasia,Pulmonology,"Inclusion: * Gestational age 25-28 completed weeks * Requiring CPAP or non-invasive positive pressure ventilation with signs of early respiratory distress. * CPAP pressure of 5-8 cm H2O and FiO2 >=0.30. * Less than 6 hours of age. * Agreement of the Treating Physician in charge of the infant's care. * Signed parental consent. Exclusion: * Previously intubated, or in imminent need of intubation * Congenital anomaly or condition that might adversely affect breathing. * Identifiable alternative cause for respiratory distress (e.g. congenital pneumonia or pulmonary hypoplasia). * Lack of availability of an OPTIMIST treatment team."
NCT07247760,PATIENT SATISFACTION AND MASKING OF WHITE SPOT LESIONS AFTER HOME WHITENING WITH 10% CARBAMIDE PEROXIDE,White Spot Lesions,Other,"Inclusion: * Be over 18 years of age. * Have white spots on teeth between 1.3 and 2.3 or between 3.3 and 4.3. * No previous dental treatment on teeth affected by hypomineralisation lesions. * No active caries lesions at any ICDAS II stage on the anterior teeth. * Patients with satisfactory oral hygiene and periodontal health, who are not undergoing periodontal maintenance and who do not use chlorhexidine mouthwashes. Patients with recessions without sensitivity are included. Exclusion: * Patients who have previously undergone whitening treatment (less than 5 years ago). * Patients undergoing orthodontic treatment. * Patients with a history of trauma to the front teeth. * Patients with endodontically treated anterior teeth. * Pregnant or breastfeeding patients. * Patients who smoke. * Patients with periodontal disease. * Patients with poor oral hygiene."
NCT03736850,Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors,Locally Advanced or Metastatic Solid Tumors,Oncology,1. Willing and able to provide written informed consent for the trial. 2. Subjects must have a histologically or cytologically confirmed advanced or metastatic solid tumor(s) for which no effective standard therapy is available or tolerable. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 4. Life expectancy ≥ 12 weeks. 5. Able to swallow and retain oral medication. 6. Subject must have adequate organ function. 7. Use of effective contraception.
NCT05367388,"A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants",Bioequivalence,Other,"Inclusion: * Must be Chinese (1st generation or 2nd generation Chinese with both Chinese parents), or Caucasian. * Body mass index between 18.0 and 30.0 kg/m2, inclusive. * In good health, determined by no clinically significant findings from medical history, physical examination, 12 lead ECG, vital sign measurements, and clinical laboratory evaluations at screening and at check-in as assessed by the Investigator (or designee). Screening clinical laboratory evaluations may be repeated once at the discretion of the Investigator. * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 1.5 × the upper limit of normal (ULN), total bilirubin ≤ 1.5 × ULN at screening and check-in. Subjects with ALT or AST >1.0 × ULN combined with total bilirubin >1.0 × ULN are excluded. * QT interval corrected for heart rate using Fridericia's method (QTcF) ≤ 450 msec confirmed by calculating the mean of the triplicate measurements within 4 weeks prior to Day 1. * Systolic blood pressure between 100 and 140 mmHg or diastolic blood pressure between 50 and 90 mmHg, confirmed by calculating the mean of the triplicate measurements within 4 weeks prior to Day 1. Major Exclusion: * Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator. * History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator. * Have positive Coronavirus Disease 2019 (COVID-19) test at screening and/or at check-in, have clinical signs or symptoms of COVID-19 as determined by the Investigator, or have ongoing significant complication(s) from prior COVID-19 infection. * Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant derived preparations within 14 days prior to check in, unless deemed acceptable by the Investigator. * Have previously completed or withdrawn from this study or any other study investigating APL 101 or similar drug product, and/or have previously received APL 101 or similar drug product."
NCT06929182,OBServaToIre interNational Des Patients AnTiphospholipidEs traités Par Anticoagulants Oraux Directs,Antiphospholipid Syndrome (APS); Direct Oral Anticoagulants (DOACs); Thrombotic and Bleeding Events; Safety,Other,"Inclusion: * Person having received complete information on the organization of the research and not having opposed the use of this data * Male or female aged 18 and over; * Carrier of a thrombotic APS according to the Sydney classification criteria, regardless of the length of time in the disease * Having received a direct oral anticoagulant (DOAC) treatment which is currently discontinued. * Or currently treated with DOAC Exclusion: * Incomplete Sydney classification criteria * Presence of a triple antiphospholipid positivity * History of arterial thrombosis * Persons referred to in Articles L. 1121-5, L. 1121-7 and L1121-8 of the French Public Health Code: * Pregnant, parturient or nursing mother * Minor person (not emancipated) * Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice) * Person of full age unable to express consent * Persons deprived of their liberty by a judicial or administrative decision, persons undergoing psychiatric treatment under Articles L. 3212-1 and L. 3213-1 of the French Public Health Code. * Signature of the research participation opposition form"
NCT02619890,Brain Glioma Registry Combining Clinical and Imaging Information,Adult Glioma,Other,"Inclusion: * Patients must have radiologically and histologically confirmed diagnosis of Brain Glioma * Life expectancy of greater than 3 months * Must receive a first- or second-line therapy * Signed informed consent Exclusion: * No brain gliomas * Patients who have any type of bioimplant activated by mechanical, electronic, or magnetic means (e.g., cochlear implants, pacemakers, neurostimulators, biostimulates, electronic infusion pumps, etc), because such devices may be displaced or malfunction * Patients who are pregnant or breast feeding; urine pregnancy test will be performed on women of child bearing potential"
NCT00440362,A Phase 1/2 Clinical Trial of an Alphavirus Replicon Vaccine for Influenza,Influenza,Other,"Inclusion: 1. Between 18 and 40 years of age, inclusive; 2. Good general health without significant physical examination findings or clinically significant abnormal laboratory results; 3. Available to participate for the entire study period of approximately 4 months; 4. For women of childbearing potential, a negative urine pregnancy test at screening and before each immunization, and agreement to consistently use contraception from 28 days prior to enrollment until the last protocol visit, for sexual activity that could lead to pregnancy; 5. Acceptable laboratory parameters: hemoglobin ≥ 11.2 g/dL for women, ≥ 12.8 g/dL for men, white blood cell count 3,300 - 12,000 cells/mm3, platelet count 125,000 - 550,000/mm3, alanine aminotransferase (ALT) within normal range for study laboratory, serum creatinine within normal range for study laboratory, normal urine dipstick (negative glucose, negative hemoglobin, and negative or trace protein), negative hepatitis B virus (HBV) and hepatitis C virus (HCV) blood tests, negative HIV blood test; 6. Willingness to have blood stored for up to 10 years for use in additional assays to evaluate immune responses to influenza or the alphavirus vector if such assays become available 7. Willingness to participate in the study as evidenced by signed informed consent obtained before screening. Exclusion: 1. Venous access deemed inadequate for the phlebotomy demands of the study; 2. Women who are breast feeding; 3. In female subjects, a positive urine pregnancy test at screening or on the day of any vaccine injection; 4. Receipt of any influenza vaccine within 12 months prior to enrollment; 5. Receipt of any other vaccine within 30 days prior to enrollment; 6. Use of any investigational agent within 30 days prior to enrollment; 7. Receipt of immunoglobulin or blood products within 60 days prior to enrollment; 8. Use of cytotoxic medications within 6 months prior to enrollment; 9. Use of systemic corticosteroids within 6 months prior to enrollment (except that participants who have completed a course of prednisone, at up to 20 mg per day for up to 7 days, at least 1 month prior to enrollment are eligible for enrollment); 10. Presence of any factor that places the individual at increased risk for severe complications from influenza; 11. History of serious adverse reactions to any vaccine, including anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema or abdominal pain; 12. History of autoimmune disease; 13. History of splenectomy; 14. History of malignancy within the last 3 years (except that participants with a diagnosis of basal cell carcinoma of the skin are eligible for enrollment); 15. Psychiatric condition that may interfere with the ability to comply with the protocol requirements. Specifically excluded are persons with history of psychosis within the past 3 years or history of suicidal attempt or gesture within the past 3 years; 16. History of medical, occupational or family problems as a result of alcohol or illicit drug use during the past 12 months; 17. Any condition which leads the investigator to believe that the participant cannot comply with the protocol requirements or that may place the participant at an unacceptable risk for participation."
NCT01575288,Oral Trehalose Therapy to Reverse Arterial Aging in Middle-Aged and Older Adults,Vascular Aging,Other,"Inclusion: * women must be postmenopausal * body mass index (BMI) <40 kg/m2 * weight stable in the prior 3 months * absence of clinical disease as determined by medical history, physical examination, blood and urine chemistries, ankle-brachial index, and a graded exercise stress test with monitoring of blood pressure and 12-lead ECG"
NCT05871203,Changes in Gene Expression and Prognosis of Blood Immune Cells After Cardiopulmonary Bypass Surgery,Acute Kidney Injury,Other,"Inclusion: * 1) Age≥ 18 years old; 2) Cardiopulmonary bypass descending valve replacement (molding), or coronary artery bypass grafting, or macrovascular surgery. Exclusion: * 1) any cognitive or mental impairment that is unable to sign the informed consent form; 2) Have basic immune system and blood system diseases; 3) pregnancy; 4) Receiving radiotherapy and chemotherapy before surgery; 5) Receiving immunosuppressive drugs within six months; 6) Have participated in other interventional clinical trials within 30 days before surgery. Exit Criteria: 1. Incomplete surgery; 2. Secondary transfer in the operating room; 3. Automatically request to terminate the test."
NCT05062954,Effects of a Polyphenol-rich Cranberry Extract on Cardiometabolic and Neurocognitive Health,Abdominal Obesity,Other,"Inclusion: * Men and women aged between 30-70 years old; * BMI equal or greater than 25 kg/m2; * Waist circumference ≥85 cm for women, ≥90 cm for men; * Stable weight in the past 3 months; * Plasma triglycerides levels ≥1.5 mmol/L for men and women; * Access to a computer and Internet. Exclusion: * Any severe uncontrolled medical, surgical, neurological or psychiatric condition; * Medication for dyslipidemias, CVD, T2D or obesity; * Medication that may affect the CNS; * Gastro-intestinal conditions or disorders likely to impact on absorption; * History of nephrolithiasis or urolithiasis; * Contraindications to MRI (cardiac pacemaker/defibrillator, cochlear implant or other ear implant, implanted insulin pump or other infusion pump systems, neurostimulator or other electronic/magnetic implant or device, any type of prothesis, aneurysm clips, any metallic fragments, vascular access port, catheter, dental retainer, claustrophobia, surgery in the last 3 months); * Anticoagulant/blood thinning medication in the last month; * Pregnant or breastfeeding women; * Substance or alcohol abuse; * Known allergy or intolerance to cranberry; * Currently smoking."
NCT04872673,The Professional Values and Ethical Sensitivities During the COVID-19 Pandemic,Professional Values; Ethical Sensitivities,Other,Inclusion: * being over the age of 18 * being a fourth level student * agreed to participate in the research Exclusion: * being diagnosed with a neuropsychiatric disease
NCT02906969,Colonoscopy Educational Video Upon Inner City Population,Other Surgical Procedures,Other,Exclusion Criteria:  Patients were excluded if they had dementia or  cognitive impairment or  if they did not have a pre-procedural office visit. Inclusion Criteria:  age 18-85  undergoing initial outpatient colonoscopy  willing to participate in and sign consent for this study  Morning session of colonoscopy procedure
NCT01652950,Study Comparing the Effectiveness of Incentives on Physical Activity Behavior in a Health Insured Population,Physical Activity Behavior; Wellness Programs,Other,"Inclusion: * Newly enrolled adult members of the Discovery Health medical plan who voluntarily registered and paid a monthly subscription for the health promotion program (Vitality) were eligible for the study. The recruitment, enrollment and random allocation to intervention arms were initiated via a web-based email communication. Initially, an opt-in design was used but because of an exceedingly low enrollment rate in the first three months of the study (less than 10%), with permission from the governing IRB, an opt-out strategy was employed for the remaining 5 months of the recruitment window, resulting in an enrollment rate of 90% during this time period. Altogether, 12121 eligible persons were recruited electronically, 1046 had invalid email addresses, 163 opted out and there was no information concerning age for 5 subjects. Exclusion: * Members who opted out. All members were voluntarily screened for participation in physical activity, and this is also done on site by participating gyms."
NCT04734613,Tai Chi for Behavioral Modification Among Individuals With Metabolic Syndrome,Metabolic Syndrome,Other,Inclusion: * diagnosis of metabolic syndrome * adults who agree to participate either behavioral modification programs for 12 weeks * be able to understand the questionnaire and follow the exercise or education program Exclusion: * who attend regular exercise program past 6 months
NCT02452970,RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy,Cholangiocarcinoma,Other,"Inclusion: * Histologically or cytologically confirmed diagnosis of biliary tract adenocarcinoma/cholangiocarcinoma * Must have locally advanced or distant metastatic disease that is not surgically curable * Failed first-line chemotherapy * Age ≥ 18 years * Life expectancy of at least 12 weeks (3 months) * Performance status 0 or 1 * Adequate liver, kidney, and bone marrow function Exclusion: * Symptomatic metastatic brain or meningeal tumors * Investigational compound within 4 weeks of enrollment * History of needing to permanently discontinue prior gemcitabine/ cisplatin regimen for reasons other than progression (i.e. toxicity) * Any medical condition which, in the investigator's opinion, makes the patient unsuitable for participation * Pregnant or nursing * Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results * Albumin <2.8 * Uncontrolled or clinically relevant ascites * Absolute contraindication for MRI imaging such as intracorporeal metal or pacemaker"
NCT00796003,A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic Syndrome,Myelodysplastic Syndrome,Other,"Inclusion: * Myelodysplastic syndrome (de novo or secondary) fitting any of the recognized French-American-British classifications: refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, chronic myelomonocytic leukemia with white blood cells less than 13,000 /mm3 * International Prognostic Scoring System (IPSS) greater than or equal to 0.5 (Intermediate-1, Intermediate-2 or high risk) by bone marrow assessment and bone marrow cytogenetics within 28 days before study registration * 20 years or older * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Normal renal and hepatic function Exclusion: * Acute Myeloid Leukemia (AML) with bone marrow blasts greater than or equal to 30% * Participants with a history of high-dose cytarabine (Ara-C) therapy (greater than 1,000 mg/m2/day) * Participants administered adrenal cortex hormones or anabolic hormones within 7 days of study initiation * Participants who have received a colony stimulating factor (CSF) formulation within 7 days of study initiation * Active double cancer * Uncontrolled cardiac disease or cognitive heart failure * Uncontrolled restrictive or obstructive pulmonary disease * Uncontrolled diabetes mellitus * Active viral or bacterial infection * Known positive serology for Human immunodeficiency virus"
NCT01738113,Open Versus Closed Kinetic Chain Exercises in Tibial Distraction Osteogenesis by Ilizarov's METHOD,Limb Length Discrepancy; Bone Deformity,Other,Inclusion: * Referred from an orthopedic surgeon with diagnosis of tibial lengthening or deformity correction by Ilizarov's external fixator. * unilateral or bilateral tibial distraction osteogenesis. Exclusion: * Patients with Ilizarov due to neurological causes (e.g. poliomyelitis) or other neuromusculoskeletal disease that could affect muscle function and innervations. * Ankle or knee joints are included in the Ilizarov frame. * Patients developed neurological complications that interfere with rehabilitation after the application of the Ilizarov apparatus.
NCT04439825,Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction,Mood,Other,"Inclusion: * Males and females between the ages of 18-75 * Subjects will be non-naive Botox users with a glabellar wrinkle severity score of 2 or 3 who are at least 20 weeks from their last BOTOX Cosmetic treatment * Subjects that understand the purpose and aspects of the study, freely sign the consent and complete the required treatment and follow up visits. Exclusion: * Males and females below the age of 18 * Subjects that received neuromodulator injections to the glabella region in the last 20 weeks * Subjects who do not meet a 2-3 wrinkle severity score in the glabellar region * Subjects who have received other invasive or semi invasive cosmetic forehead or glabellar treatments * Subjects who have had a change in antidepressant or anti- anxiety medication in last 6 weeks * Subjects with severe depression, bipolar disorder, pregnant, * Subjects who are pregnant, attempting to get pregnant, or breast feeding * Subjects with a known allergy or sensitivity to any component of the study ingredients. * Subjects that do not understand the purpose and aspects of the study, do not sign the consent and do not complete the required treatment and follow up visit will also be excluded."
NCT03144583,Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy,Leukemia; Lymphoma,Oncology,"Inclusion: * Diagnosis of leukemia or CD19 + lymphoma, with a life expectancy less than 2 years that meet the following conditions:- Adult acute lymphoid leukemia in second or third response, not candidate for transplantation due to age, associated diseases or lack of donor, or in relapse post allogeneic transplant.- Pediatric acute lymphoid leukemia in second or third response, refractory or non-transplant candidate due to donor absence, or in relapse post allogeneic transplant, or with minimal residual residual disease (0.1% or greater) after two or more lines of treatment. - Symptomatic follicular lymphoma, which has received at least 2 treatment regimens (one of them including rituximab) and a progression-free interval of less than 2 years. Patients not candidates for transplantation or post-transplant relapse may be included.- Symptomatic chronic lymphocytic leukemia, which has received at least 2 treatment regimens (one of them including rituximab) and a progression-free survival of less than 2 years. Patients with a 17p deletion or TP53 mutation may be included after the first line of treatment. - Mantle cell lymphoma in the first relapse (or higher) when it is not a candidate for transplantation, or second post-transplant relapse (or higher). - Diffuse large cell lymphoma in first relapse (or higher) when it is not a candidate for transplantation, or second post-transplant relapse (or higher). * Age greater than 2 years and less than 80. * ECOG functional status from 0 to 2 * Life expectancy of at least 3 months. * Appropriate venous access to perform an apheresis procedure. Absence of contraindications for it. * Signature of informed consent (patient or legal guardian). Exclusion: * Treatment with any experimental or non-marketed substance within four weeks prior to recruitment, or actively participating in another therapeutic clinical trial. * Diagnosis of another past or present neoplasm. Patients may be included in complete remission for more than 3 years, or with a history of non-melanoma skin cancer or completely resected in-situ carcinoma. * Central nervous system involvement (CNS-3) at inclusion. Inclusion will be permitted with patients with a lower grade (CNS-2) or with CNS-3 who have responded to intrathecal chemotherapy. * Early relapse after allogeneic transplantation (less than 3 months for apheresis of mononuclear cells, less than 6 months for infusion of ARI-0001) or patients on active immunosuppressive therapy for graft-versus-host disease (corticosteroids or other systemic immunosuppressants ). * Active infection requiring systemic medical treatment such as chronic kidney infection, chronic lung infection or tuberculosis. * HIV infection. * Concurrent and uncontrolled medical illnesses including cardiac, renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological or psychiatric diseases which in the opinion of the researcher represent a risk to the patient. * Positive serology for hepatitis B, defined as a positive test for HBsAg. In addition, if the patient is HBsAg negative but has anti-HBc antibodies it will be necessary to perform a DNA test of the hepatitis B virus, and if the result is positive the patient will be excluded. * Positive serology for hepatitis C, defined as a positive test for anti-HCV antibodies confirmed by RIBA. * Severe organ failure, defined as a cardiac ejection fraction 3 times the upper limit of normal (unless it is due to CLL or Gilbert syndrome). * Pregnant or lactating women. Women of childbearing potential should have a negative pregnancy test in the screening phase. * Women of childbearing age, including those whose last menstrual cycle was in the year prior to screening, who are unable or unwilling to use highly effective contraceptive methods from the start of the study to the end of the study. * Men who are unable or unwilling to use highly effective contraceptive methods from the start of the study to the completion of the study. * The need to take glucocorticoids in a chronic manner at doses higher than 10 mg / day of prednisone (or equivalent) or other chronic immunosuppressants. Hormonal contraceptives, intrauterine device, intrauterine systems of hormonal release, sexual abstinence, vasectomy of the couple or bilateral tubal occlusion."
NCT00944697,A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy,Moderate to Severe Pain Due to Diabetic Polyneuropathy,Neurology,Inclusion: * Moderate to severe pain due diabetic polyneuropathy * Opioid-naive subjects Exclusion: * Females who are pregnant or lactating * Subjects with evidence of significant structural abnormalities of the gastrointestinal tract * Subjects with evidence of impaired liver/kidney function upon entry into the study
NCT06000423,Tranexamic Acid to Reduce Contraceptive-related Bleeding Side Effects,Bleeding; Contraceptive Device; Complications,Other,"Inclusion: * English or Spanish speaking * In good general health * Have etonogestrel (ENG) subdermal contraceptive implant (must be palpable to prove that an ENG implant is in place at time of screening and enrollment) * Experience frequent or prolonged bleeding while using ENG implant (>7 days of continuous bleeding/spotting in the last 30 days, or 2 or more episodes of bleeding/spotting in the last 30 days) * Implant use for at least 30 days prior to screening visit * Willing to continue using the implant for at least 30 days from study enrollment * Access to a reliable cell phone and must be willing to receive and respond to a daily text or email message to assess bleeding and use of study drug * Negative gonorrhea/chlamydia screening performed at screening visit Exclusion: * Centers for Disease Control Medical Eligibility for Contraceptive use category 3 or 4 for contraceptive usage * Currently pregnant * Less than 6 months postpartum, less than 6 weeks abortion, not breast/chest feeding (cessation of lactation at least 6 weeks prior to enrollment) * Undiagnosed abnormal uterine bleeding pre-dating placement of contraceptive implant * Bleeding dyscrasia * Anticoagulation use * Active cervicitis * Allergy to Tranexamic Acid * Known renal insufficiency * History of venous thromboembolism * Current or past breast or uterine malignancy * Concurrent use of P450 pathway inducing drug * Implant is due to be switched out in 2 months or less from enrollment * Routine or chronic use of non-steroidal anti-inflammatory drugs (NSAIDs once daily or >= 14 days per month) * Currently using oral contraceptives in addition to implant (to be eligible, needs to have 4-6 week washout period) * Prior pregnancy occurred while Nexplanon/Implanon was in place * Chronic use of Cannabidiol, THC, or marijuana (>3 times per week) (patients could have used Cannabidiol, THC, or marijuana chronically in the past, but must have a washout time period of no use for at least one month prior to the study) * Chronic use of cigarettes (>1 cigarette per week) (patients could have used cigarettes chronically in the past, but must have a washout time period of no use for at least six months prior to the study)"
NCT02578303,Association Between Cerebral Arterial Vascular Flow and Sleep Apnea in Neurodegenerative Alterations,Alzheimer Disease,Other,"Inclusion: 1. Elderly patients about or over 75 years 2. Any gender 3. Dementia Group: 3.1. MMSE (Mini Mental State Examination)> 15 3.2. Diagnosis of dementia established according to DSM-IV 3.3. Dementia of the Alzheimer type from NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association) 4. Control Group: Preserved cognitive function corresponding to a normal MMSE score by the standards of Poitrenaud 5. Ability to understand and give consent freely (for demented subjects, a legal representative will be delegate) Exclusion: 1. Elderly patients under 75 years 2. Anyone with a classic contraindication to MRI 2.1 Major behavioral disorders that do not allow the realization of MRI in optimal conditions 2.2 Claustrophobia 2.3 Presence of foreign non-compliant material 2.4 Presence of intraocular metal body 3. Having a history of chest surgery or neurosurgical 4. Chronic respiratory failure 5. Suffering from dementia other than that associated with Alzheimer's disease 6. Patients with a handicap 7. Patients under legal protection"
NCT07126561,Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers,"HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2",Oncology,"Inclusion: * 1.1.1 Participants must agree to provide written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. 1.1.2 Participants must be ≥ 18 years of age at the time of consent. 1.1.3 Participants must have histologically confirmed locally advanced unresectable and/or metastatic esophageal, gastric or GEJ adenocarcinoma per AJCC, 8th edition. 1.1.4 Participants must have measurable disease according to RECIST 1.1 within 42 days prior to registration. 1.1.5 Participants must have an ECOG PS of Grade 2 within 28 days prior to registration. 1.1.6 Participants must NOT be candidates for combination therapy per treating provider judgement. 1.1.7 Participants must have HER2 protein overexpression or HER2 gene amplification in tumor tissue (preferred on tumor tissue biopsy if available) or liquid biopsy. (Note: HER2 levels considered positive Score 3+ on IHC, Score of 2+ with positive results of FISH) 1.1.8 Prior definitive chemoradiation therapy for localized disease, systemic therapy including immunotherapy in the adjuvant setting is allowed. 1.1.9 Prior cancer treatment in the adjuvant setting must be completed at least 3 months prior to registration and the participant must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to Grade ≤ 1 or baseline. 1.1.10 Participants must demonstrate adequate organ and bone marrow function within 28 days before registration as described in the table below. Organ and bone marrow function criteria must also be met when laboratory tests are repeated within 3 days before Cycle 1 Day 1. 1.1.1 Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to registration. A negative result for serum pregnancy test (test must have a sensitivity of at least 25 mIU/mL) must be available at the screening visit and urine beta-human chorionic gonadotropin (β-HCG) pregnancy test prior to each administration of IMP. Women of childbearing potential are defined as those who are not surgically sterile (i.e. underwent bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy) or post-menopausal. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. 1.1.2 Females of childbearing potential who are sexually active with a male able to father a child must be willing to abstain from penile-vaginal intercourse or must use at least one highly effective method of contraception from the time of first exposure to study intervention until 7 months after the final dose. They must also refrain from breastfeeding or donating ova /retrieving ova for their own use for the same time period. 1.1.3 Males able to father a child who are sexually active with female of childbearing potential must be willing to abstain from penile-vaginal intercourse or must use at least one highly effective method of contraception from the time of first exposure to study intervention until 4 months after the final dose. They must also refrain from freezing or donating sperm during the same time period. 1.1.4 All participants must be able to understand and comply with study procedures for the entire length of the study, as determined by the enrolling physician or protocol designee. Exclusion: * 1.1.1 Prior systemic therapy in the metastatic setting is not allowed, including no prior HER2-directed therapy. However, prior palliative radiation therapy is allowed. 1.1.2 Participants who are eligible for combination therapy are excluded. 1.1.3 Participants who are mismatch repair (MMR) deficient and/or MSI High as determined by institutional standards are not eligible for this study. 1.1.4 Participants who have an LVEF Grade 2 for at least 3 months prior to first exposure to study intervention and managed with standard of care treatment) that the investigator deems related to previous anticancer therapy, including: * Chemotherapy-induced neuropathy * Fatigue * Residual toxicities from prior immuno-oncology treatment: Grade 1 or Grade 2 endocrinopathies which may include: 1. Hypothyroidism/hyperthyroidism 2. Type 1 diabetes 3. Hyperglycemia 4. Adrenal insufficiency 5. Adrenalitis 6. Skin hypopigmentation (vitiligo) 1.1.6 Participants with an active primary immunodeficiency, known uncontrolled active human immunodeficiency virus (HIV) infection, or active hepatitis B (HBV) or C (HCV) virus infection are excluded. Note: Hepatitis B/C serology is required; HIV testing is not required unless required by local policy. * NOTE: Participants with past or resolved HBV infection are eligible only if they meet all of the following criteria: * HBsAg (-) (for > 6 months off anti-viral treatment); * Anti-HBc (+) (IgG or total Ig); * HBV DNA undetectable; * Liver architecture normal (absence of any liver pathology including absence of cirrhosis or fibrosis on prior imaging or biopsy; * Absence of HCV co-infection or history of HCV co-infection; * Access to a local Hepatitis B expert during and after the study; Those participants must be closely monitored for HBV reactivation. Further instructions for monitoring and management of participants at risk of Hepatitis B reactivation (those with HBsAg (-), anti-HBc (+) (IgG or total Ig) serology) are provided in Appendix I. • NOTE: Participants positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA. 1.1.7 Participants with a medical history of myocardial infarction (MI) within 6 months before study registration or symptomatic congestive heart failure (New York Heart Association Class II to IV) are not eligible. Participants with troponin levels above ULN at screening, and without any myocardial related symptoms, should have a cardiologic consultation before enrollment to rule out MI. 1.1.8 Participants with a history of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. 1.1.9 Participants with a history of any of the following lung criteria are excluded: * Lung-specific intercurrent clinically significant illnesses including, but not limited to, any underlying pulmonary disorder (e.g., pulmonary emboli within three months of registration, severe asthma, severe chronic obstructive pulmonary disorder, restrictive lung disease, pleural effusion, etc.) * Any autoimmune, connective tissue or inflammatory disorders, including Rheumatoid arthritis, Sjogren's, and sarcoidosis, where there is documented, or a suspicion of pulmonary involvement at the time of screening. Full details of the disorder should be recorded in the eCRF for participants who are included in the study. * Prior pneumonectomy (complete), 1.1.10 Participants who have spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms are not eligible. Participants with clinically inactive brain metastases may be included in the study. Participants with treated brain metastases that are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants may be included in the study if they have recovered from the acute toxic effect of radiotherapy. A minimum of 2 weeks must have elapsed between the end of whole brain radiotherapy and study registration. 1.1.11 Participants with uncontrolled infection requiring IV antibiotics, antivirals, or antifungals. 1.1.12 Participants with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen, per treating physician discretion, are not eligible for this trial. 1.1.13 Participants who have received treatment with any investigational anti-cancer drug within 2 weeks prior to registration are excluded. Washout periods for other therapies are listed below: Treatment Minimum Washout Chloroquine/Hydroxychloroquine ≥ 14 days Radiation Therapy including palliative stereotactic radiation therapy to chest ≥ 4 weeks Palliative stereotactic radiation therapy to other anatomic areas including whole brain radiation ≥ 2 weeks 1.1.14 Participants who have received live, attenuated vaccine (mRNA and replication deficient adenoviral vaccines are not considered attenuated live vaccines) within 30 days prior to study registration are excluded. NOTE: Participants, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of study intervention. 1.1.15 Participant has substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions, that may, in the opinion of the investigator, interfere with the subject's participation in the clinical study or evaluation of the clinical study results. 1.1.16 Participant has Corrected QT interval (QTcF) prolongation to > 470 msec (females) or >450 msec (males) based on average of the screening triplicate12-lead ECG. 1.1.17 Participant has a known allergy or hypersensitivity to study treatment or any of the study drug excipients. 1.1.18 Participant has a history of severe hypersensitivity reactions to other monoclonal antibodies. 1.1.19 Participant has multiple primary malignancies within 3 years, with the exception of: adequately resected non-melanoma skin cancer, curatively treated in-situ disease. other solid tumors curatively treated 1.1.20 Participant has a pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal shunt, or Cell-free and Concentrated Ascites Reinfusion Therapy (CART)."
NCT00405990,Male Partner Involvement in the Prevention of MTCT of HIV,HIV Infections,Infectious Disease,"Inclusion: * To be eligible for participation, a woman must be less than 30 weeks pregnant at enrolment. Exclusion: * Women who are more than 30 weeks pregnant will be excluded."
NCT03013296,Delinieation of GIP's Effects During a Meal in Humans Using GIP Receptor Antagonisation (GA-4),Glucose Metabolism Disorders,Other,"Inclusion: * Normal kidney function, liver function and hemoglobin levels. Exclusion: * Medication, Diabetes type 1 or 2, BMI > 27, first degree relatives with Type 2 Diabetes"
NCT06924190,Pharmacokinetics and Bioequivalence Study of Budesonide Inhalation Aerosol in Humans,Bioequivalence Study in Healthy Subjects,Other,"Inclusion: 1. **Age**: Chinese male or female subjects aged 18 to 65 years (inclusive of the boundary values). 2. **Weight**: Males must weigh ≥50.0 kg, and females must weigh ≥45.0 kg. The Body Mass Index (BMI) calculated as [ text{BMI} = /frac{/text{weight (kg)}}{/text{height}^2 (/text{m}^2)} ] must be between 19.0 and 26.0 kg/m² (inclusive of the boundary values). 3. **Informed Consent**: Subjects must fully understand the purpose, nature, methods, and potential adverse reactions of the trial and voluntarily sign a written informed consent form. 4. **Communication and Compliance**: Subjects must be able to communicate effectively with the investigator, correctly use the inhaler device after training, and understand and comply with all the requirements of the study. Exclusion: 1. **Examination**: Subjects with clinically significant abnormalities in physical examination, vital signs, ECG, chest X-ray, complete blood count, urinalysis, or biochemical blood tests; subjects with serum potassium levels below the lower limit of normal. 2. **Examination**: Subjects with positive test results for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV), human immunodeficiency virus antigen and antibody (HIV), or syphilis antibody. 3. **Examination**: Subjects with a measured FEV1/predicted FEV1 ≤ 80% or FVC ≤ 80% of the predicted value in pulmonary function tests; or subjects whose pulmonary function test results are judged by the investigator to indicate small airway disease. 4. **Inquiry**: Subjects with a history or current diagnosis of chronic or severe diseases of the liver, kidneys, endocrine system, urinary system, digestive system, blood, or lymphatic system. 5. **Inquiry**: Subjects with a history or current diagnosis of chronic or severe respiratory diseases. 6. **Inquiry**: Subjects with a history or current diagnosis of chronic or severe cardiovascular diseases (especially ischemic heart disease, hypertension, aneurysm, paroxysmal tachycardia, etc.). 7. **Inquiry**: Subjects with a history or current diagnosis of chronic or severe nervous system diseases; or subjects with a history of frequent headaches or dizziness, or those who have experienced headaches or dizziness within one week before screening. 8. **Inquiry**: Subjects with a history of allergy to budesonide, its excipients, or other corticosteroid components; or subjects with a known history of allergies to two or more food or environmental substances, or a history of atopic allergic diseases (urticaria, rash, eczematous dermatitis, etc.). 9. **Inquiry**: Subjects with a history or current diagnosis of glaucoma, cataracts, or blurred vision. 10. **Examination**: Subjects with current oral ulcers, pharyngitis, or enlarged tonsils. 11. **Inquiry**: Subjects who consumed excessive amounts of tea, coffee, or caffeine-containing beverages (8 cups or more per day, 1 cup = 250 mL) within three months before screening, or those who do not agree to abstain from these beverages during the trial. 12. **Inquiry**: Subjects who consumed food that may affect drug metabolism (including grapefruit or grapefruit products, dragon fruit, mango, pomelo, etc.) within 48 hours before screening, or those who do not agree to abstain from such food during the trial. 13. **Inquiry**: Subjects with special dietary requirements that prevent adherence to a uniform diet, or those with difficulty swallowing. 14. **Inquiry + Examination**: Subjects who cannot tolerate venipuncture or have a history of fainting due to blood or needles, or those with difficulty in blood collection. 15. **Inquiry**: Subjects who have undergone surgery that the investigator judges may affect drug absorption, distribution, metabolism, or excretion; or those who plan to undergo surgery within four weeks before screening or during the trial. 16. **Inquiry**: Subjects who used any medication (prescription drugs, over-the-counter drugs, health supplements, vaccines, herbal medicines, etc.) within 30 days before screening. 17. **Examination**: Subjects with a positive alcohol breath test result (breath alcohol content > 0.0 mg/100 mL). 18. **Inquiry**: Subjects with a history of alcohol abuse within the past year (consuming ≥14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine) or those who cannot abstain from alcohol during the trial. 19. **Inquiry**: Subjects who smoked ≥5 cigarettes per day within three months before screening or those who cannot quit smoking during the trial. 20. **Examination**: Subjects with a positive urine nicotine test result. 21. **Inquiry + Internet Screening**: Subjects who participated in any drug clinical trial within three months before screening and received medication, or those who plan to participate in other clinical trials during this study. 22. **Inquiry**: Subjects who donated blood or had significant bleeding (more than 400 mL) within three months before screening; or those who plan to donate blood or blood components during the study or within three months after the study ends. 23. **Examination**: Subjects with a positive urine drug abuse screening result. 24. **Inquiry**: Subjects with a history of drug abuse within the past five years. 25. **Inquiry + Examination**: Pregnant or breastfeeding women, or women of childbearing age who had unprotected sexual intercourse with their partners within 14 days before screening. 26. **Inquiry**: Female subjects who used long-acting estrogen or progesterone injections or implants within six months before screening. 27. **Inquiry**: Male subjects (or their partners) or female subjects who plan to conceive or donate sperm or eggs during the entire trial period and within three months after the study ends, and are unwilling to take appropriate contraceptive measures. 28. Subjects with poor compliance. 29. Subjects who may not be able to complete the study for other reasons, or those whom the investigator deems unsuitable for enrollment."
NCT01526382,Use of PiCCO System in Critically Ill Patients With Septic Shock and Acute Respiratory Distress Syndrome,Septic Shock; Acute Respiratory Distress Syndrome,Other,"Inclusion: Patients were included if they were diagnosed with Shock, Acute respiratory distress syndrome (ARDS), or both. Shock was defined by the presence 4 criteria: * Heart rate of at least 90/min; * A respiratory rate of at least 20/min or a PaCO2 of 32mmHg or lower or the use of mechanical ventilation; * The use of vasopressors to maintain a systolic blood pressure of at least 90mmHg despite fluid resuscitation, low dose of dopamine (≤ 5 μg/kg per minute), or dobutamine; * at least 1 of 3 signs of hypoperfusion (urine output < 0.5mL/kg of body weight per hour for 1 hour or more; neurologic dysfunction defined by confusion, psychosis, or a Glasgow coma scale score of ≤ 6; plasma lactate higher than the upper limit of the normal value). Acute respiratory distress syndrome： * the presence of acute decrease in PaO2/FIO2 to 200mmHg or lower, * bilateral pulmonary infiltrates or a chest radiograph consistent with edema; * no clinical evidence of left atrial hypertension; and requirement for positive pressure ventilation. Exclusion: * Patients were moribund. * signed do-not-resuscitation odor."
NCT05536661,Impact of Tear Substitute Use on Dry Eye in Gamers.,Evaporative Dry Eye,Other,"Inclusion: * 18 years or older * Participants in videogame convention planning to play video games for a minimum of 6 hours daily for the next 3 days. * Voluntarily accept to participate and sign informed consent form Exclusion: * Ocular, nasolagrimal or palpebral active condition different from dry eye disease. * History of ocular trauma or infecction in the last 3 months previous to inclusion. * History of refractive surgery. * Visual acuity 0.5 or less in at least 1 eye. * Ocular medication use in the 3 days prior to inclusion. * History of systemic condition asociated to dry eye. * Use of systemic medication known to induce dry eye in the last 30 days. * Known allergy to hyaluronic acid. * Pregnant or lactating women."
NCT00480259,Hyperproteic Nutrition:Correlation of BUN to Nitrogen Balance,Enteral Feeding,Other,"Inclusion: * Greater then or equal to 18 years of age and patient in Intensive Care Unit * Receiving enteral nutrition, with expected duration of at least 5 days * Blood urea nitrogen and creatinine clearance are part of routine blood work * Indwelling urinary catheter in place Exclusion: * Renal or hepatic failure * Current or history(past 6 mos) of GI bleeding * Serum creatinine on day of screening of equal to or greater then 1.5 mg/dl * Creatinine Clearance on day of screening of equal to or less then 30ml/min * Hypovolemia resulting in increased BUN * Septic shock * Blood urea nitrogen on day of screening equal to or greater then 30mg/dl"
NCT01845350,Safety of Autologous M2 Macrophage in Treatment of Non-Acute Stroke Patients,Ischemic Stroke; Hemorrhagic Stroke,Neurology,"Inclusion: * Computed tomography confirmed ischemic or hemorrhagic stroke * Duration since stroke onset more than 3 and less than 12 months * Age between 18 and 75 years old * Persistent neurological deficits more than 4 points in NIHSS stroke scale * Signed informed consent Exclusion: * The history of previous stroke * Seizures * Thrombophilias or primary hematological diseases * Malignancy * Hepatic or renal dysfunctions * Hemodynamic or respiratory instability * Autoimmune disease * HIV or uncontrolled bacterial, fungal, or viral infections * Pregnancy * Participation in other clinical trials"
NCT00060554,A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN),Myocardial Infarction; Coronary Disease,Cardiology,"Inclusion: * Scheduled for PCI, including PCI for non-ST elevation acute coronary syndromes (ACS), primary PCI for ST elevation myocardial infarction (MI) or elective PCI (with planned overnight stay in hospital). (Patients undergoing diagnostic heart catherization who are suitable candidates for ""ad hoc"" PCI are also eligible). Exclusion: * Age 200 seconds immediately prior to PCI * Use of low molecular weight heparin (LMWH) in the previous 6 hours before PCI * Currently receiving an oral anticoagulant (OAC) agent with an INR > 1.8 * Thrombolytic therapy for ST elevation MI in the previous 24 hours before PCI * Active internal bleeding or history of hemorrhagic diathesis * Thrombocytopenia (platelet count < 100 x 10-9/L) * Pregnant women or women of childbearing potential who are not using an effective method of contraception * Known allergy to unfractionated heparin, fondaparinux, aspirin or clopidogrel * Absolute contra-indication to anticoagulation * Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of enrollment or prior participation in this study."
NCT03708627,Bimatoprost as a Treatment for Graves' Orbitopathy,Graves Ophthalmopathy,Other,"Inclusion: Graves' Ophthalmopathy with Exophthalmos/Proptosis - Exclusion: Active Graves Disease, Currently pregnant, Taking Steroids"
NCT00418990,Effect of Vitamins on Academic Performance of School Children,Malnutrition,Other,Inclusion: * Enrollment in third through sixth grades in the Archdiocese of Newark School System during 2004-2005 academic year. * Completion of the Assessment of Skills and Knowledge Exam in 2003 Exclusion: * Known allergy to any ingredients of the multivitamin. * Currently taking a multivitamin on a regular basis.
NCT01535989,Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma,B-cell Lymphoma Refractory,Oncology,"Inclusion: * Histologically and/or cytologically confirmed relapsed or refractory CD22+ B-cell Non Hodgkin's Lymphomas * No limitations on prior treatments. Patients must have progressed after at least one prior therapy. * Adult patients (aged > 18yrs old). * ECOG status ≤ 1. * Life expectancy greater than 3 months. * Adequate organ and marrow function. Exclusion: * Uncontrolled intercurrent illness * Chronic obstructive or chronic restrictive pulmonary disease * Hepatitis B, C and HIV * Patients with known known central nervous system lymphoma involvement."
NCT05135013,The Association of Hormonal Intake and Demographic Factors With Breast Cancer Risk. An Egyptian Case-controlled Study,Observational Study,Other,Inclusion: * Age > 18 and < 70 Exclusion: * Diagnosed with other concurrent malignancies. * A prior history of another cancer.
NCT00759070,Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism,HIV Infections,Infectious Disease,"Inclusion: * Chronic HIV-1 infection * Age 18 or above * Antiretroviral-naive * Criteria for antiretroviral therapy in accordance with current guidelines * Plasma LDL-cholesterol below 190 mg/dL * Not receiving lipid-lowering agents * Written informed consent Exclusion: * Use of phytosterol-enriched food previous month. * Pregnancy or breastfeeding * Cardiovascular disease * Secondary Hypercholesterolemia * Plasma creatinine above 1,2 mg/dL) * Aminotransferases above 5 times ULN * Current treatment for hepatitis C coinfection * Diabetes mellitus (fasting glycemia > 124 mg/dL) * Illegal drug use or alcohol abuse * Active AIDS-defining opportunistic disease"
NCT05213182,Peer Support Intervention to Mitigate Social Isolation and Stigma of Adolescent Motherhood in Zimbabwe,"Mental Health Disorder; Social Isolation; Stigma, Social",Other,Inclusion: * Adolescent mothers (pregnant and/or have a child or children) aged 14-18 years living in the intervention or control communities. Exclusion: * Individuals who are not adolescent mothers aged 14-18 years and who do not live in the intervention or control communities. * individuals with an acute or severe illness or disability (e.g. psychosis) that results in a functional impairment that substantially interferes with the ability to provide informed consent and participate in the study.
NCT01195090,Adding Sitagliptin or Pioglitazone to Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin and Sulfonylurea,Type 2 Diabetes,Endocrinology,"Inclusion: * Type 2 diabetes patients who were treated with stable doses of sulfonylurea and metformin to their half maximally dose (sulfonylureas > half maximal dose, and metformin > 1500 mg/d) for > 10 weeks * > 20 years old * A1C: > 7.0 % and 1.4 mg/dl), alanine aminotransferase or aspartate aminotransferase levels > 2.5 times the upper limit of normal * Current or prepare to pregnancy and lactation"
NCT07375394,3D-Printed Extraoral Camera for Standardized Dental Photography,Malnutrition,Other,Inclusion: * Undergraduate dental students * Egyptian nationality * Both genders Exclusion: * Postgraduate dental students * Incomplete questionnaires * Refusal to participate
NCT02011061,Validation of Coronary Calcium Subtraction to Improve Diagnostic Accuracy of Coronary CT Angiography,Coronary Artery Disease,Cardiology,"Inclusion: * Age > 55 Years * Scheduled for invasive coronary angiography * Logistically possible to perform CCTA before invasive evaluation Exclusion: * Known Iodine-contrast allergy * Estimated GFR below 50 ml/min * Atrial fibrillation or other persistence cardiac arrythmia * Contraindication to betablockers (bronchospasm, LVEF less than 40%) * Implanted PM or ICD * Previous mechanical heart valve surgery * Inability to maintain breath-hold for at least 5 sec * Patient-related condition resulting the inability of the patient to understand the informed consent form of the study"
NCT02711176,Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection,Helicobacter Infection,Infectious Disease,"Inclusion: * The patients who proved H. pylori infection following three methods * Positive rapid urease test * Histologic evidence of H. pylori by modified Giemsa staining * Positive stool Antigen Test Exclusion: * Patients who received eradication therapy for H. pylori infection, previously * H. pylori eradication failure because of poor compliance * The administration of antibiotics or the consumption of bismuth salts within 4 weeks or the administration of a proton pump inhibitor (PPI) within 2 weeks * Advanced gastric cancer or other malignancy * Abnormal liver function or liver cirrhosis * Abnormal renal function or chronic kidney disease * Other severe concurrent diseases * Previous allergic reactions to the study drugs * Pregnant or lactating women"
NCT03024450,Trastuzumab Based Therapy in HER2 Positive AGC,Gastric Adenocarcinoma,Other,"Inclusion: 1. pathology and medical imageology proven advanced gastric adenocarcinoma, inoperable; 2. received trastuzumab plus chemotherapy as the first-line palliative chemotherapy; 3. with measurable lesion with a diameter 20 mm using conventional computed tomography (CT) or magnetic resonance imaging (MRI) scans or 10 mm using spiral CT scans; 4. Eastern Cooperative Oncology Group performance status (ECOG PS ) of 0-2; 5. left ventricular ejection fraction(LVEF) more than 50 percents; 6. sufficient bone marrow, liver and renal function. Exclusion: 1. received previous systemic therapy for advanced disease (except adjuvant/neoadjuvant chemotherapy completed at least 6 months before enrollment); 2. trastuzumab based adjuvant/neoadjuvant therapy; 3. treatment with any other anticancer therapy (lapatinib, immunotherapy, etc); 4. patients with heart failure, coronary artery disease or myocardial infarction within the previous 6 months. 5. trastuzumab based first line therapy started beyond 4 weeks from the first diagnoses of AGC."
NCT03078140,Iodine Supplement Strategies Between Routine Iodine Supplementation and Selective Iodine Supplementation,Pregnancy Related; Iodine Deficiency,Other,"Inclusion: * first visit for antenatal care in the first trimester * singleton pregnancy * delivered at Maharaj Nakorn Chiangmai Hospital Exclusion: * thyroid disease which diagnosed before pregnancy or currently * history of thyroid gland surgery or iodine ablation therapy * received iodine supplement before pregnancy * received any medication for thyroid disease treatment, within 6 weeks postpartum women or breast feeding period * family history of thyroid disease * having underlying disease or contraindication which cannot received iodine supplement * loss follow-up or incomplete data."
NCT03274856,A Study of GLWL-01 in Patients With Prader-Willi Syndrome,Prader-Willi Syndrome,Other,"Inclusion: * Confirmed diagnosis of PWS based on genetic confirmation using DNA method * Body mass index (BMI) of 27 to 60 kg/m2 * No evidence of weight excursion beyond 10% of baseline weight * Patients must provide assent and have a reliable caregiver (must have been caring for the patient for at least 6 months) who provides a separate written informed consent to participate. The caregiver is expected to be the primary caregiver throughout the study and must be in frequent contact with the patient (defined as at least 4 awake hours per day). The caregiver must be able to communicate with site personnel and in the investigator's opinion must have adequate literacy to complete questionnaires. If a caregiver cannot continue, 1 caregiver replacement is allowed * Are on a stable diet and exercise regimen for >2 months prior Exclusion: * Current enrollment in or discontinuation within the last 30 days from a clinical trial involving any investigational drug or device * Are currently living in a group home for more than 50% of the time * A history or presence of other medical illness that indicates a medical problem that would preclude study participation * Have an estimated glomerular filtration rate 300 μg/mg) or hematuria * Are hypertensive (defined as sitting systolic blood pressure (BP) greater than or equal to (≥)140 millimeters of mercury (mmHg) and diastolic BP ≥90 mmHg) * Patients on weight loss medications within 30 days of dosing, or with a history of bariatric surgery * Unable to refrain from or anticipates the use of: 1. Any drugs known to be significant inhibitors of Cytochrome P450, family 3, subfamily A (CYP)3A enzymes and/or P-glycoprotein (P-gp) including regular consumption of grapefruit or grapefruit juice for 14 days prior to the first dose. Acetaminophen (up to 2 grams per 24-hour period) may be permitted 2. Any drugs known to be significant inducers of Cytochrome P450, family 3, subfamily A (CYP3A) enzymes and/or P-gp, including St. John's Wort 3. Any medications that prolong the QT/QTc interval, unless the participant has been stable on the medication for at least 3 months and has a corrected QT interval (QTc) 10 mg per day, atorvastatin >20 mg per day, or lovastatin >20 mg per day, or have a history of statin-induced myopathy/rhabdomyolysis * Unsuitable for inclusion in the study in the opinion of the investigator"
NCT06352346,A Single-case Design to Investigate a Compensatory Brain Game Supporting Goal Management Training Intervention in a Psychiatric Brain Injury Population,Acquired Brain Injury; Depressive Symptoms; Anxiety; Executive Dysfunction,Neurology,"Inclusion: * Age: 18 - 75 years * Non-progressive acquired brain injury * Minimal time post-onset of 3 months * Receive inpatient neuropsychiatric care at the time of inclusion * Executive deficits (neuropsychological assessment) * Reasonable amount of awareness in their deficits, at least to the extent that they are motivated and capable to learn new skills with respect to their executive performance. Exclusion: * Inability to speak/understand the Dutch language * Severe psychiatric disorders such as psychosis, manic episode, severe disruptive behavior * Neurodegenerative disorders (i.e. dementia, Huntington, Parkinson * Substance abuse (active) * Severe cognitive comorbidity (i.e. Korsakov) * Aphasia * Neglect * Unable to look at a computer screen for 15 minutes * Unable to operate a keyboard or computer mouse"
NCT06970925,Pilot Study Evaluating the Advantages of Sucrosomial® Iron Post-operative Supplementation vs Standard of Care After Cardiac Surgery,Cardiac Surgery,Cardiology,"Inclusion: * ICU hospitalized patients who underwent non-emergent cardiac surgery * Post operative iron deficient or anemic patients (Hb 18 years Exclusion: * Post operative day 1 Hg 90 years * Patients with cancer or other chronic conditions that impair erythropoiesis (e.g. MDS) * Stage 3, 4 renal disease * Intraoperative transfusion of PRBC"
NCT01391468,Beneficial Effect of Probiotics on Chronic Kidney Disease,Chronic Kidney Disease,Other,"Inclusion: 1. receiving peritoneal dialysis for more than 3 months, at least 18 years of age, and GFR < 15 ml/min. 2. receiving hemodialysis dialysis for more than 3 months, at least 18 years of age, and GFR < 15 ml/min. 3. Stage 3 and 4 CKD patients Exclusion: * active infectious conditions within the last 30 days, * pregnancy for female, * autoimmune disease e.g. SLE., * cardiovascular events before."
NCT07115173,Clinical Trial to Evaluate the Efficacy of Probit-Based Triple Therapy for Helicobacter Pylori Eradication,Helicobacter Infection,Infectious Disease,"Inclusion: 1. Male or female, aged 19 to 75 years at consent. 2. Confirmed H. pylori positive by urease breath or enzyme test. 3. Require eradication therapy due to at least one condition: chronic atrophic gastritis, peptic ulcer, history of early gastric cancer or adenoma resection, functional dyspepsia, low-grade MALT lymphoma, idiopathic thrombocytopenic purpura, iron deficiency anemia, hyperplastic polyps, or family history of gastric cancer. 4. Agree to use medically acceptable contraception during the trial (including medically sterile women such as menopausal, hysterectomy, tubal ligation, or bilateral oophorectomy). 5. Provide voluntary written informed consent. Exclusion: 1. History of receiving H. pylori eradication therapy prior to study participation. 2. Known hypersensitivity to the investigational product, penicillin-class antibiotics, or macrolide-class antibiotics. 3. Current use of medications contraindicated with the investigational product or concomitant therapy. 4. Abnormal laboratory values in blood chemistry tests as defined by the protocol. 5. pregnant or nursing women"
NCT00280176,"Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer",Colorectal Cancer,Oncology,"DISEASE CHARACTERISTICS:  Biopsy confirmed diagnosis of adenocarcinoma of the rectum meeting 1 of the following clinical staging criteria:  T3-T4, N0, M0 (stage II disease)  T4 disease defined as tumor fixed on examination or involving adjacent pelvic structures, such as the sidewall, bladder, uterus, prostate, or small bowel by ultrasound or CT scan  Any T, N1-2, M0 (stage III disease)  Any T, any N, M1 (stage IV disease)  Recurrent disease (any prior stage)  Candidate for local palliative therapy or curative resection of metastatic disease  Previously treated CNS disease allowed provided it is stable for > 3 months PATIENT CHARACTERISTICS:  ECOG performance status 0-2  Life expectancy > 3 months  Adequate nutrition  WBC ≥ 4,000/mm³  ANC > 2,000/mm³  Platelet count ≥ 100,000/mm³  Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 30 mL/min  Bilirubin ≤ 1.5 mg/dL  Not pregnant or nursing  Negative pregnancy test  Fertile patients must use effective contraception  No s"
NCT01952483,Effect of Vitamin D Replacement on Immune Function and Cognition in MS Patients,Multiple Sclerosis (MS),Other,"Inclusion: 1. Definite diagnosis of Multiple Sclerosis following the revised McDonald MS diagnostic criteria 2. Male and Female Aged 18 and above 3. On interferon-β treatment (Rebif®, Avonex®, or Betaseron®) 4. No signs of active inflammation or attack or new lesions on MRI Exclusion: 1. Treatment with immune modulating/ suppressive drugs other than IFN-b within 6 weeks prior to enrolment 2. Pregnancy 3. Hypercalcemia 4. eglomerular filtration rate<60 5. History of primary hyperparathyroidism, hypercalcemia, renal dysfunction, cardiac disease, malignancy, or granulomatous disease 6. The occurrence of an exacerbation (defined as an episode of neurologic dysfunction lasting at least 24 hours) within 4 weeks of enrollment 7. History of dementia or related disorders 8. History of traumatic brain injury 9. Diagnosis of epilepsy or history of seizure 10. Diagnosis of psychiatric disease, substance abuse/dependence, alcohol abuse/dependence 11. Currently, on any of the following medications Lithium, or Thiazide diuretics"
NCT00314262,Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor,Precancerous Conditions,Oncology,"Inclusion: * Participants must have premalignant lesions. * Lesion sites include oral cavity, oropharynx, and larynx. * Must have at least a >20 pack-year history of smoking. * Must have a Eastern Cooperative Oncology Group (ECOG)/Zubrod performance status of 0-1. * Participants must be 18 years of age or older. * No contraindications for laryngoscopy and biopsy. * Adequate liver function. * Must have hemoglobin and hematocrit levels at or above the lower limit of the normal range. * Participants must have prothrombin time (PT)/partial thromboplastin time (PTT) levels at or above the lower limit of the normal range. * Women of child-bearing potential must have a negative serum pregnancy test within 72 hours of receiving treatment. * Must be able to swallow the oral dose of erlotinib and celecoxib. * Participants must be disease free. * Final eligibility will be determined by the health professionals conducting the trial. Exclusion: * Participants with acute intercurrent illness or those who had surgery within the preceding 4 weeks unless they have fully recovered. * History of previous malignancies unless the cancer was stage I or II and rendered free of disease more than 1 year. * Pregnant or breast feeding. * Not practicing adequate contraception if the participants are of child bearing potential. * Female patients who have a positive pregnancy test. * History or recent myocardial infarction. * Hypertension not adequately controlled by medication. * Documented history of coagulopathy. * Documented history of congestive heart failure (CHF) greater than New York Heart Association (NYHA) Grade II. * Participants who were taking COX-2 inhibitors or EGFR tyrosine kinase inhibitors within 3 months of study entry. * Documented history or interstitial lung disease. * Known connective tissue disease. * History of nonsteroidal antiinflammatory drug (NSAID)-induced ulcers or those who are at risk for a GI ulcer. * Participated in a clinical trial of an investigational drug within 12 months prior to enrollment. * Final eligibility will be determined by the health professionals conducting the trial."
NCT05238246,Effect of a Humanoid Robot on Dental Anxiety in Children,"Behavior, Child",Other,Inclusion: * healthy children * no previous dental experience * need pulpotomy in at least one mandibular primary molar Exclusion: * Children showing definitely negative behaviour (Frankl 1) during dental prophylaxis at the first visit.
NCT05775588,Long-term Effects of Endobronchial Valve Implantation on Cardiac Function and Skeletal Muscle Function,Chronic Obstructive Pulmonary Disease,Pulmonology,"Inclusion: * Patients with Chronic Obstructive Pulmonary Disease * FEV1 ≤ 45% pred and FEV1/FVC 100% pred and RV>175% pred * CAT score≥18 * Emphysema damage>50% * Complete interlobar fissure >95% based on quantitative analysis of CT measurement * No smoking>6 months * Sign the informed consent form Exclusion: * PaCO2>8.0 kPa, or PaO2 50mmHg * Anticoagulant therapy that cannot be stopped before surgery * Patients with obvious immune deficiency * Participated in other lung drug studies within the first 30 days of this study * Pulmonary nodules requiring intervention * Any disease or condition that interferes with the completion of the initial or subsequent assessment"
NCT00699517,A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies,Sarcoma,Other,"Inclusion: * Histologically proven soft tissue sarcoma * Unresectable locoregional recurrent or metastatic soft tissue sarcoma * Failure of a previous anthracycline-based regimen administered recommended dose and of prior ifosfamide therapy Exclusion: * Less than 3 weeks elapsed from prior treatment with radiotherapy, surgery, or chemotherapy to the time of randomization * Brain metastases and carcinomatous leptomeningitis * Uncontrolled hypertension * Known platinum hypersensitivity The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial."
NCT00437970,Medication in Early Diabetes (MED) Study,"Diabetes Mellitus, Type 2",Endocrinology,Inclusion: * Drug naïve Indigenous Australians with Type 2 Diabetes * Permanent resident of Darwin for at least 1 year immediately before and expected to be for at least 1 year after study commences * Participants must be able to give informed voluntary consent * Both males and females (females of child bearing potential excluded if not on reliable means of contraception)
NCT02046070,Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma,Multiple Myeloma,Other,"Inclusion: Each participant with newly diagnosed multiple myeloma (NDMM) must meet all of the following inclusion criteria to be enrolled in the study: 1. Adult male or female participants 18 years of age or older with a confirmed diagnosis of symptomatic multiple myeloma (MM) according to standard criteria. 2. Participants for whom cyclophosphamide and dexamethasone treatment is appropriate and who are considered not eligible for high-dose therapy (HDT)-stem cell transplantation (SCT) for 1 or more of the following reasons: * The participant is 65 years of age or older. * The participant is less than 65 years of age but has significant comorbid condition(s) that are, in the opinion of the investigator, likely to have a negative impact on tolerability of HDT-SCT. Each participant with relapsed and/or refractory multiple myeloma (RRMM) must meet all of the following inclusion criteria to be enrolled in the study: 1. Adult male or female participants 18 years or older with a confirmed diagnosis of symptomatic MM either currently or at the time of initial diagnosis, according to standard criteria, and relapsed and/or refractory disease after 1 to 3 lines of prior therapy. A participant is considered to have refractory disease if disease progression occurred during the treatment period or within 60 days of receiving the last dose of a given therapy. A line of therapy is defined as 1 or more cycles of a single-agent or combination therapy or a sequence of planned treatments such as induction therapy followed by autologous stem cell transplantation (ASCT) and then maintenance therapy. 2. No evidence of graft-versus-host disease for participants who have undergone prior allogeneic stem cell transplantation. In addition, all participants (NDMM and RRMM) must meet all of the remaining criteria: 1. Participants must have measurable disease defined by at least 1 of the following 3 measurements: * Serum M-protein ≥ 1 g/dL (≥ 10 g/L). * Urine M-protein ≥ 200 mg/24 hours. * Serum free light chain assay: involved free light chain level ≥ 10 mg/dL (≥ 100 mg/L), provided that the serum free light chain ratio is abnormal. 2. Participants must meet all of the following clinical laboratory criteria: * Absolute neutrophil count (ANC) ≥ 1000/mm^3 and platelet count ≥ 75,000/mm^3. Platelet transfusions to help participants meet eligibility criteria are not allowed within 3 days prior to administration of the study drug. * Total bilirubin ≤ 1.5 x the upper limit of the normal range (ULN). * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x ULN. * Calculated creatinine clearance (CrCL) ≥ 30 mL/min. 3. Eastern Cooperative Oncology Group performance status of 0, 1, or 2. 4. Female participants who: * are postmenopausal for at least 1 year before the screening visit, or * are surgically sterile, or * If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 90 days after the last dose of study drug, or * agree to practice true abstinence over the period previously described, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [ie, calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception.), and * adhere to any treatment-specific pregnancy prevention guidelines for cyclophosphamide and dexamethasone. 5. Male participants, even if surgically sterilized (ie, status post-vasectomy), who: * agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, or * agree to practice true abstinence over the period previously described, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods for the female partner] and withdrawal are not acceptable methods of contraception.), and * adhere to any treatment-specific pregnancy prevention guidelines for cyclophosphamide and dexamethasone. 6. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care. 7. Suitable venous access for the study-required blood sampling. 8. Is willing and able to adhere to the study visit schedule and other protocol requirements. Exclusion: 1. Prior treatment for multiple myeloma with either standard of care treatment or investigational regimen (for participants with NDMM only). NOTE: Prior treatment with corticosteroids (maximum dose of corticosteroids should not exceed the equivalent of 160 mg of dexamethasone over 14 days. Localized radiation is permitted as long as it is below a therapeutic level and administered at least 14 days prior to the first dose of study treatment. 2. Diagnosis of smoldering MM, Waldenström's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome, plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative syndrome. 3. Central nervous system involvement. 4. Diagnosed or treated for another malignancy within 2 years before the first dose or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection. 5. Peripheral neuropathy Grade 1 with pain or Grade 2 or higher peripheral neuropathy of any cause on clinical examination during the Screening period. 6. Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of study drug, including difficulty swallowing. 7. Infection requiring intravenous (IV) antibiotic therapy or other serious infection within 14 days before the first dose of study drug. 8. Ongoing or active infection, known human immunodeficiency virus (HIV) positive, active hepatitis B or C infection. 9. Systemic treatment with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort within 14 days before the first dose of study treatment. 10. Known allergy to any of the study medications, their analogues, or excipients in the various formulations. 11. Major surgery within 14 days before the first dose of study drug. (Note: kyphoplasty or vertebroplasty is not considered major surgery.) 12. Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period. 13. Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol. 14. Comorbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the participant inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens. 15. Treatment with any investigational products for reasons other than MM within 30 days before the first dose of study drug."
NCT07364708,AC Deflation in Descemet's Membrane Detachment,Descemet's Membrane Disorder,Other,Inclusion: * Patients with post cataract surgery DM detachment diagnosed within 1st week postoperatively. * Patient age ranges from 50 to 70 years old. Exclusion: * Less than one third of Descemet's Membrane is included. * Post-operative infection or severe inflammation. * Patient with pre-existing glaucoma.
NCT06082141,Effect of Adding TTPB to SAPB in Breast Cancer Surgery,Acute Pain; Opioid Use,Other,"Inclusion: * ASA I-II-III * BMI 20 to 35 kg / m2 * Patients scheduled for breast cancer surgery procedure Exclusion: * Patients with previously known allergies to the drugs to be used in the study, * Infection near the puncture site, * Patients with previous symptoms of neurological disease (TIA, syncope, dementia, etc.) * Known coagulation disorders, * Alcohol and drug use, * Disorder of consciousness, * Opioid use equal to or greater than 60 mg oral morphine equivalent per day, * Patients with pre-existing neuropathic pain, * Liver failure, renal failure, cardiac failure * Morbid obesity (body mass index [BMI] > 35 kg m-2) * Uncontrolled diabetes mellitus * Women during pregnancy or breastfeeding * Not approving the informed consent form"
NCT06111274,A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer,Advanced Pancreatic Cancer,Oncology,"Inclusion: * Male and female aged 18-75 years old. The subjects must have informed consent to the study, and signed the written informed consent voluntarily. * Diagnosis as non resectable local advanced or metastatic pancreatic cancer by histology or cytology. * Measurable disease as defined by RECIST 1.1. * Without systemic treatment for pancreatic cancer. * ECOG physical strength score 0-2 * Estimated survival time >=3 months. * The adequate bone marrow fuction and coagulation function Exclusion: * Known allergy or hypersensitivity to any components of the investigational drug product. * Previous treatment with highly selective inhibitors targeting Colony Stimulating Factor 1 (CSF-1)/Colony Stimulating Factor 1 Receptor (CSF-1R). * With Breast Cancer Gene 1/2 (BRCA1/2) gene mutation. * With a history of other malignancies within 5 years. * During the trial, other chemotherapy, targeted therapy, hormone therapy, immunotherapy, radiotherapy (except for local symptomatic radiotherapy) or traditional Chinese medicine must be used for anti-tumor treatment. * With conditions that significantly affected the absorption of oral drug. * Surgical treatment is required within 4 weeks before the first administration, or unhealed, infected, or dehiscence of previous surgical wounds. * During the 2 weeks prior to the first administration of this study, the patient was receiving chronic systemic steroid treatment or any other form of immunosuppressive treatment. * Concomitant use of strong inhibitors or inducers of Cytochrome P450 3A4 (CYP3A4) within 14 days prior to randomization. * Previous peripheral neuropathy > grade 1 (Common Terminology Criteria for Adverse Events, version 5.0). * Diagnosed with immune deficiency or interstitial lung disease. * The patients were vaccinated within 4 weeks before the first treatment. * Participated in any drug clinical trial within 4 weeks before the first treatment. * Active central nervous system (CNS) metastases. * Impaired cardiac function or clinically significant cardiac disease. * Known active liver or biliary disease, or other diseases that may lead to abnormal liver function test results during the study. * Known active infections from certain viruses, bacteria or parasites. * Patients with refractory/uncontrolled ascites or pleural effusion. * Pregnant or lactating women. * Any other clinically significant comorbidities, which in the judgment of the Investigator, should not be included."
NCT01438879,Lymphocytic Herpesviruses and Cerebrospinal Fluid Polymerase Chain Reaction (PCR),Central Nervous System Infection,Infectious Disease,"Inclusion: * Immunocompetent patients with clinical symptoms and signs of central nervous system infections and CSF pleocytosis (pleocytosis group) * Immunocompetent patients without suspicion of CNS infection and no CSF pleocytosis (non-pleocytosis group) Exclusion: * Suspicion of CNS-infection, eg. encephalitis, but no CSF leukocytosis (pleocytosis group) * Patients without symptoms of CNS infection, but who has CSF pleocytosis of unknown origin (non-pleocytosis group)"
